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ABSTRACT: We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives
developed as CB1 receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [
35S]GTPγS binding
assay, and in a competition association assay that enables the relatively fast kinetic screening of multiple compounds. The
compounds show high affinities and a diverse range of kinetic profiles at the CB1 receptor and their structure−kinetic relation-
ships (SKRs) were established. Using the recently resolved hCB1 receptor crystal structures, we also performed a modeling study
that sheds light on the crucial interactions for both the affinity and dissociation kinetics of this family of ligands. We provide
evidence that, next to affinity, additional knowledge of binding kinetics is useful for selecting new hCB1 receptor antagonists in
the early phases of drug discovery.
■ INTRODUCTION
Within the endocannabinoid system (ECS), two human can-
nabinoid receptor subtypes have been identified: the human CB1
(hCB1) receptor and the human CB2 (hCB2) receptor.
1 They
are members of the rhodopsin-like class A G-protein-coupled
receptors (GPCRs) and are primarily activated by endogenous
cannabinoids (endocannabinoids, ECs), including anandamide
(or N-arachidonylethanolamine, AEA) and 2-arachidonoylgly-
cerol (2-AG).1,2 The hCB1 and hCB2 receptors show 44% overall
sequence homology and display different pharmacological pro-
files.3 The hCB1 receptor is present in the central nervous system
(CNS) and is widely distributed in the peripheral nervous system
(PNS) and peripheral tissues,2,4 including heart, liver, lung, gastro-
intestinal tract, pancreas, and adipose tissue.5,6 The presence of the
hCB1 receptor within both the CNS and PNS mediates neuro-
transmitter release and controls various cognitive, motor, emotional,
and sensory functions. Furthermore, activation in the peripheral
tissues contributes to energy balance and metabolic processes.6−9
The broad presence of the hCB1 receptor in a variety of
complex physiological systems provides numerous opportunities
for therapeutic intervention. In the particular case of obesity, the
ECS, including the hCB1 receptor, is overactive, with increased
levels of endocannabinoids in plasma, both in central and periph-
eral tissues.10 Therefore, blockade of the hCB1 has been explored
for the treatment of obesity. With this in mind, rimonabant
(SR141716A, Figure 1a), a hCB1 receptor inverse agonist, was
developed by Sanofi-Aventis and introduced in Europe in 2006.
However, it was quickly withdrawn from the market due to unac-
ceptable psychiatric side effects.11−13 Many other hCB1 receptor
antagonists entered into clinical trials, such as taranabant (MK-0364,
Figure 1b)14 and otenabant (CP945598, Figure 1c).15However, they
were not developed further due to similar psychiatric side effects
despite their diverse chemical structures.
To avoid the CNS side effects, peripherally acting hCB1
receptor antagonists with physicochemical features that reduce
brain penetration have been developed.16 Another approach
has been the development of hCB1 receptor neutral antagonists
because it has been postulated that the CNS side effects of
rimonabant were due to its inverse agonism.17−19
Drug target binding kinetic parameters are receiving increasing
attention, alongside classical affinity (Ki) and potency (IC50)
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values, as has been discussed for several other class A GPCRs.
In particular, the receptor−ligand residence time (RT) is emerg-
ing as an additional parameter to assess the therapeutic potential
of drug candidates with respect to drug efficacy and safety.20−22
In the research field of GPCRs, a number of structure−kinetic
relationship (SKR) studies have been published and the results
suggest that the strategic combination of SKR with classic
structure−affinity relationships (SAR) can improve the resulting
decision process.23−26 By doing so, ligand−receptor interactions
can be better understood, as together they not only comprise the
equilibrium state of a ligand−receptor interaction but also its
metastable intermediates and/or transition states.27 The binding
kinetics driven drug discovery approach for the hCB1 receptor
has been validated in some aspects already by its applica-
tion in the development of allosteric modulators of the hCB1
receptor.28,29
In the current study, we report the synthesis and evaluation
of 1,2-diarylimidazol-4-carboxamide derivatives (Figure 1d), as
human CB1 receptor antagonists with more polar characteristics
than rimonabant.30,31 Together with rimonabant, they were eval-
uated in a radioligand displacement assay, a [35S]GTPγS binding
assay, and a dual-point competition association assay that enables
the relatively fast kinetic screening of compounds.32 Selected
compounds were progressed to a full competition association
assay. The compounds show high affinities and a diverse range
of kinetic profiles at the hCB1 receptor, which allowed their
structure−kinetic relationships (SKRs) to be established. Their
putative binding mode was analyzed using the recently resolved
crystal structures of the hCB1 receptor,
33,34 shedding light on key
structural features of the receptor binding site that are involved in
ligand recognition and dissociation. Thus, we provide evidence
that, in additional to affinity, knowledge of binding kinetics is
useful for selecting new hCB1 receptor antagonists in the early
phases of drug discovery.
■ RESULTS AND DISCUSSION
Chemistry. The synthesis of the 1,2-diarylimidazol-4-car-
boxamide scaffold commenced from commercially available
4-(benzyloxy)aniline 1, which was converted to the 2,4-dichloro-
benzamidine 2 (Scheme 1). After a one-pot condensation and
Figure 1. Chemical structures of (a) rimonabant, (b) taranabant,
(c) otenabant, and (d) the scaffold of 1,2-diarylimidazol-4-carboxamides
as CB1 receptor antagonists; the R
1 substitution is defined as the “left
arm” of the scaffold while the R2 substitution defines the “right arm” of
the scaffold. The calculations of PSA values are reported in Supporting
Information.
Scheme 1. Synthesis of Antagonists 8a, 8b, and 11a−ha
aReagents and conditions: (a) EtMgBr, 2,4-diClPhCN, THF, rt, 20 h, 98%; (b) (i) EtO2CC(O)CH(Br)CH3, K2CO3, THF, rt, 66 h, (ii) AcOH,
reflux, 1 h, 65%; (c) HBr, AcOH, rt, 15 h, 63%; (d) R1-OH, DEAD, Ph3P, THF, toluene, rt, 15 h, 77%; (e) KOH, EtOH:THF:H2O 2:2:1, 50 °C,
3.5 h, 95%; (f) (i) (COCl)2, DMF cat., CH2Cl2, rt, 90 min, (ii) piperidin-1-amine·HCl, pyridine, CH2Cl2, rt, 2 h, 55% (2 steps); (g) KOH,
MeOH:H2O 3:1, reflux, 2 h, 99%; (h) (i) (COCl)2, DMF cat., CH2Cl2, reflux, 2 h, (ii) piperidin-1-amine, NEt3, CH2Cl2, 0 °C to rt, 2 h, 74%;
(i) BBr3, CH2Cl2, rt, 1 h, 58%; (j) R
1-X, base, CH2Cl2. Corresponding 56−90% R1 substitutions are listed in Table 1.
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cyclization sequence, the core-imidazole 3 was obtained. After-
ward, either saponification of the ethyl ester or acidic hydrolysis
of the benzyl ether of 3 led to intermediates 4 and 5, respectively.
Subsequently, Mitsunobu reaction on intermediate 5 yielded
mono- and trifluoropropyl ether derivatives 6a and 6b. After
saponification of the ethyl esters of 6a and 6b, the corresponding
Table 1. In Vitro Pharmacology Data, Including Conventional Antagonism, Binding Affinities, and KRI Values, for Human CB1
Receptor Antagonists with Various “Left Arm” R1 Substitutions
code R1 [35S]GTPγS binding pIC50 ± SD or SEM (mean IC50 in nM)
a pKi
b ± SEM (mean Ki in nM) KRI
c
8a −CH2CH2CF3 8.3 ± 0.1 (5.6)d 9.1 ± 0.2 (1.26) 0.90 (0.90, 0.89)
8b −CH2CH2CH2F 8.2 ± 0.01 (6.0)d 10 ± 0.2 (0.34) 1.09 (1.34, 0.84)
9 −CH2Ph 7.7 ± 0.1 (18)d 8.2 ± 0.1 (6.28) 0.90 ± 0.20
11a −CH2CH2CH2CF3 8.9 ± 0.1 (1.2) 9.7 ± 0.1 (0.32) 0.80 (0.85, 0.75)
11b −SO2CH2CH2CH3 8.7 ± 0.03 (1.8)d 9.6 ± 0.1 (0.28) 0.59 ± 0.06
11c −SO2CH2CH2CH2F 8.5 ± 0.2 (3.1)d 9.5 ± 0.2 (0.32) 0.88 (1.00, 0.75)
11d −SO2CH2CH2CF3 9.0 ± 0.03 (1.1) 9.9 ± 0.1 (0.11) 1.02 (1.08, 0.96)
11e −SO2CH2CH2CH2CH3 8.9 ± 0.05 (1.3)d 9.9 ± 0.1 (0.18) 0.77 ± 0.25
11f −SO2CH2CH2CH2CF3 8.9 ± 0.1 (1.2) 10 ± 0.2 (0.062) 0.93 (0.89, 0.97)
11g −SO2CH2CH2CH(CH3)2 8.9 ± 0.1 (1.3) 9.7 ± 0.1 (0.20) 1.02 (1.06, 0.97)
11h −SO2CH2CH2C(CH3)3 8.7 ± 0.1 (2.4) 9.3 ± 0.1 (0.60) 0.73 (0.68, 0.78)
apIC50 ± SD (n = 2) or SEM (n ≥ 3), obtained from [35S]GTPγS binding on recombinant human CB1 receptors stably expressed on HEK-293 cell
membranes. bpKi ± SEM (n = 3), obtained from radioligand binding assays with [
3H]CP55940 on recombinant human CB1 receptors stably
expressed on CHO cell membranes. cKRI ± SEM (n = 3) or KRI (n1, n2) (n = 2), obtained from dual-point competition association assays with
[3H]CP55940 on recombinant human CB1 receptors stably expressed on CHO cell membranes. dn = 2.
Scheme 2. Synthesis of Antagonists 14a−14h, 19, (±)-22, (±)-25, and 28a
aReagents and conditions: (a) (i) SOCl2, reflux or (COCl)2, DMF cat., CH2Cl2, rt, (ii) R
2-NH2, NEt3, CH2Cl2, 17−98% (2 steps), or 2-amino-5-
trifluoromethylpyridine, Me3Al, CH2Cl2, rt to 45 °C, 16 h, 64%; (b) BF3·OEt2, Me2S, CH2Cl2, rt, or HBr, AcOH, rt, 20−97%; (c) Et3N,
F3CCH2CH2SO2Cl, CH2Cl2, −78 °C, 25−97%; (d) (i) TBDMSCl, Et3N, CH2Cl2, rt, 22 h, (ii) Boc2O, THF, rt, 4 h, 70% (4 steps, a, b, d i, and d ii),
(iii) TBAF, THF, rt, 90 min, (iv) F3CCH2CH2SO2Cl, Et3N, CH2Cl2, −78 °C, 3 h, (v) SOCl2, MeOH, 0 °C to rt, 1 h, 56% (3 steps, d iii., d iv, and
d v); (e) (i) (COCl)2, DMF cat., CH2Cl2, rt, 2 h, (ii) Cl3CCH2OH, NEt3, CH2Cl2, rt, 3 h, 95% (2 steps, e, b); (f) Zn, AcOH, 3 h; (g) (i) (COCl)2,
DMF cat., CH2Cl2, rt, 2 h, (ii) 4-aminocyclohexanol, NaOH, H2O:CH2Cl2 2:1, rt, 2 h, 54% (2 steps, f, g); (h) CH2O, NaBH4, NaBH3CN, CH3CN,
H2O, AcOH, rt, 48 h, 32%. Corresponding R
2 substitutions are listed in Table 2.
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Table 2. In Vitro Pharmacology Data Including Conventional Antagonism, Binding Affinity, and KRI Values for Human CB1
Receptor Antagonists with Various “Right Arm” R2 Substituents
apIC50 ± SD (n = 2) or SEM (n ≥ 3), obtained from [35S]GTPγS binding on recombinant human CB1 receptors stably expressed on HEK-293 cell
membranes. bpKi ± SEM (n = 3), obtained from radioligand binding assays with [
3H]CP55940 on recombinant human CB1 receptors stably
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carboxylic acids (7a and 7b) were transformed to acid chlorides
and reacted with piperidin-1-amine to yield the corresponding
amides (8a and 8b). Alternatively, the rest of the series was
produced from intermediate 4 by first introducing the piperidin-
1-amide. Lewis acid-catalyzed cleavage of benzyl ether 9 followed
by substitution of the released alcohol 10 with various alkyl
halides gave the corresponding ethers 11a−11h, completing the
“left arm” series of antagonists (Table 1).
The synthesis of the “right arm” series of antagonists was
started from intermediate 4 (Scheme 2). Using various amines
and the aforementioned acid chloride introduction/amide
formation sequence, amides 12a−12h were obtained as well as
racemic (±)-20. Deprotection of the aromatic alcohol on 12a−
12h and subsequent sulfonylation using 3,3,3-trifluoropropane-
1-sulfonyl chloride gave compounds 14a−14h. After depro-
tection of racemic (±)-20 however, it was found that direct sub-
stitution was not possible, therefore a series of protecting group
manipulations was executed on (±)-21 to end up with (±)-22.
Toward (±)-25, (±)-20 was first dimethylated and subsequently
debenzylated and sulfonylated, giving (±)-25. Exploring alter-
native synthesis routes, compound 19 was synthesized, with a
few extra steps, by first esterifying 4 with 2,2,2-trichloroethanol,
followed by deprotection of the aromatic alcohol. Sulfonylation
of the released alcohol, saponification of the trichloroethylester,
acid chloride formation, and subsequent amide formation gave
19. To obtain trifluoromethylpyridine derivative 28, conven-
tional methods as described for the industrial production of
rimonabant were applied,35 starting with the direct amidation of
ethyl ether 3 followed by debenzylation and sulfonylation.
Biology. All 1,2-diarylimidazol-4-carboxamide derivatives
were evaluated as antagonists in an in vitro [35S]GTPγS binding
assay on HEK-293 cell membrane fractions overexpressing the
human CB1 receptor. We also determined the functional activity
of nine representative antagonists on the human CB2 receptor.
The data in Table 1 and Supporting Information, Table S1 shows
that all compounds tested had higher functional activity for
the human CB1 receptor over the human CB2 receptor, with
approximately 110−570-fold selectivity.
Likewise, they were also tested in a [3H]CP55940 radioligand
displacement assay on membrane fractions of CHO cells over-
expressing the recombinant human CB1 receptor. These results
are reported in Tables 1 and 2. We found that, although using
different cellular background and assay systems, there is a sig-
nificant correlation (r2 = 0.49, P = 0.0001) between the affinity
(pKi) values from the radioligand binding assay and the potencies
(pIC50) determined in the [
35S]GTPγS binding assay (Figure 2).
We subsequently determined the binding kinetics of the 1,2-dia-
rylimidazol-4-carboxamide derivatives in a competition associa-
tion assay with [3H]CP55940 as the probe after a validation step.
[3H]CP55940 Binding Kinetic Assay. Receptor association
and dissociation rate constants of [3H]CP55940 were directly
determined in classic radioligand association and dissociation
experiments at 30 °C. The binding of [3H]CP55940 approached
equilibrium after approximately 25 min (Figure 3), yielding a kon
(k1) value of (1.4 ± 0.08) × 10
6 M−1 s−1. Binding of the radio-
ligand was reversible after the addition of rimonabant (10 μM),
although the dissociation was rather slow. Even 240 min after the
addition of rimonabant, residual receptor binding (∼15%) of
[3H]CP55940 was observed. The dissociation rate constant, koff
(k2), of [
3H]CP55940 from the hCB1 receptor was (1.5 ± 0.2) ×
10−4 s−1. The kineticKD value (koff/kon) of [
3H]CP55940was 0.12±
0.03 nM (Table 3). The residence time (RT) of [3H]CP55940
was calculated as 114 ± 16 min.
Validation of the [3H]CP55940 Competition Association
Assay for Human CB1 Receptor. With the kon (k1) and koff (k2)
values of [3H]CP55940 binding established from classical asso-
ciation and dissociation experiments, kon (k3) and koff (k4) of
unlabeled CP55940 were determined by fitting the values based
on the mathematical model as described in the Experimental
Section.36 In this validation experiment, we tested three different
concentrations of unlabeled CP55940, corresponding to IC25, IC50,
and IC75 (Figure 4a). Values for kon and koff determined by this
competition association method were (1.2 ± 0.1) × 106 M−1 s−1
and (6.5 ± 1.0) × 10−4 s−1, respectively. The kon value was in
good agreement with the kon (k1) value determined in the clas-
sical association experiment (Table 3). The koff value obtained by
this method was also similar to that found in the classical kinetic
dissociation experiments with [3H]CP55940, with just a 4-fold
Table 2. continued
expressed on CHO cell membranes. cKRI ± SEM (n = 3) or KRI (n1, n2) (n = 2), obtained from dual-point competition association assays with [
3H]
CP55940 on recombinant human CB1 receptors stably expressed on CHO cell membranes.
dn = 2.
Figure 2. Correlation between the affinities/potencies of the CB1
receptor antagonists measured in a radioligand binding assay (X-axis)
and in a GTPγS binding assay (Y-axis) (r2 = 0.49, P = 0.0001). Data
taken from Tables 1 and 2
Figure 3. Association and dissociation profile of [3H]CP55940
(2.9 nM) at recombinant hCB1 receptors stably expressed on CHO
cell membranes at 30 °C. After 120 min of association, unlabeled
rimonabant (10 μM) was added to initiate the dissociation. Association
data was fitted in Prism 6 using one-phase exponential association (n = 3,
combined and normalized). Dissociation data was fitted using one-phase
exponential decay (n = 4, combined and normalized). Data are shown as
mean± SEM from at least three separate experiments each performed in
duplicate.
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difference between the values (Table 3). To confirm the robust-
ness of the assay with unlabeled human CB1 receptor antago-
nists, an experiment was performed using rimonabant (Figure 4b,
Table 4). The kon and koff values determined by this competition
association method were (2.3 ± 0.3) × 105 M−1 s−1 and (1.4 ±
0.2) × 10−3 s−1, respectively, demonstrating that rimonabant
behaves as a short residence time antagonist (14 ± 2.0 min), in
good agreement with findings reported earlier.37,38
Screening of hCB1 Receptor Antagonists Using the Dual-
Point Competition Association Assay. The competition
association assay described above is quite laborious and time-
consuming. Therefore, a so-called “dual-point competition asso-
ciation assay” for the hCB1 receptor was developed according to
the concept that we had previously established for the adenosine
A1 receptor.
32 To this end, [3H]CP55940 and unlabeled antag-
onists were coincubated at concentrations equal to, or 2−3-fold
higher than their Ki/IC50 values, which had been determined in
the [3H]CP55940 displacement assay. The so-called kinetic rate
index (KRI) was calculated by dividing the specific radioligand
binding at 30min (t1) by the binding at 240min (t2). Antagonists
with a KRI value larger than 1 indicate a slower dissociation
rate and thus a longer RT than [3H]CP55940 and vice versa.
Furthermore, it was observed that the KRI values of the hCB1
receptor antagonists had no obvious correlation with their affin-
ities (Figure 5a).
Structure−Affinity Relationships (SARs) versus Struc-
ture−Kinetic Relationships (SKRs).The 1,2-diarylimidazol-4-
carboxamide derivatives are rimonabant bioisosteres, in which
the 2,4-dichlorophenyl, amide, aryl, and methyl moieties are main-
tained on an alternative heterocyclic diazo core (Figure 1a,d). The
derivatives included in this study differ in their substituents at the
Table 3. Comparison of Equilibrium Binding and Kinetic Parameters of CP55940 Determined Using Different Methodsa
assay Ki or KD (nM) kon (M
−1 s−1) koff (s
−1)
displacementb 0.56 ± 0.04 NAc NA
association and dissociationd 0.12 ± 0.03 (1.4 ± 0.08) × 106 (1.5 ± 0.2) × 10−4
competition associatione 0.54 ± 0.10 (1.2 ± 0.1) × 106 (6.5 ± 1.0) × 10−4
aData are presented as means ± standard error of the mean (SEM) of at least three independent experiments performed in duplicate. bEquilibrium
displacement of [3H]CP55940 from hCB1 receptor at 30 °C.
cNot applicable. dClassic association and dissociation parameters of [3H]CP55940
measured in standard kinetic assays at 30 °C. eAssociation and dissociation parameters of CP55940 measured in competition association assays at
30 °C.
Figure 4. (a) Competition association experiments with [3H]CP55940
binding to recombinant hCB1 receptors stably expressed on CHO cell
membranes (30 °C) in the absence or presence of 3.5, 11, and 35 nM of
unlabeled CP55940 (n = 3, combined and normalized). (b) Competi-
tion association experiments with [3H]CP55940 binding to recombi-
nant hCB1 receptors stably expressed on CHO cell membranes (30 °C)
in the absence or presence of 120 nM of unlabeled Rimonabant (n = 6,
representative graph). t1 is the radioligand binding at 30 min, while t2 is
the radioligand binding at 240 min.
Table 4. Kinetic Parameters (kon, koff, and RT) of Selected
Human CB1 Receptor Antagonists
code kon
a (M−1 s−1) koff
b (s−1) RTc (min)
11b (3.0 ± 0.5) × 105 (2.2 ± 0.2) × 10−4 78 ± 5
14f (7.2 ± 3.2) × 105 (2.7 ± 0.5) × 10−4 62 ± 10
28 (3.5 ± 0.7) × 105 (7.8 ± 0.3) × 10−5 260 ± 56
rimonabant (2.3 ± 0.3) × 105 (1.4 ± 0.2) × 10−3 14 ± 2.0
akon ± SEM (n = 3), obtained from competition association assays with
[3H]CP55940 on recombinant human CB1 receptors stably expressed on
CHO cell membranes. bkoff ± SEM (n = 3), obtained from competition
association assays with [3H]CP55940 on recombinant human CB1 recep-
tors stably expressed on CHO cell membranes. cRT = 1/(60 * koff); RT
is expressed in min, whereas koff is expressed in s
−1
Figure 5. (a) Negative logarithm of the affinities of the hCB1 receptor
antagonists used in this study had no obvious linear correlation with
their KRI values (r2 = 0.04, P = 0.33). (b) Negative logarithm of
[35S]GTPγS IC50 values of the hCB1 receptor antagonists in this study
had no obvious linear correlation with their KRI values (r2 = 0.12, P =
0.10).
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R1 and R2 positions, which are at the “left” and “right” arms of the
scaffold, respectively (Figure 1d).
We were conscious that compound polarity may influence the
activity parameters being studied, so polarity was determined by
both calculated and experimental methods. Calculated methods
included polar surface area (PSA),39 ACDlogD7.4 with pKa cor-
rection,40 and AZlogD7.4,41 which were supplemented with
experimentally determined Log D values. A PSA of 90 Å2 has
been described as a threshold value below which penetration of
the blood−brain barrier is more likely and thus serves as an
indicator for potential to have CNS activity.42 The calculated
PSA values (Supporting Information, Tables S2 and S3) of most
of the compounds in this study were above 90 Å2, suggesting that
they would have low blood−brain barrier penetration and be
better suited for peripheral antagonism of the hCB1 receptor.
We observed that neither affinities nor KRI values of the CB1
receptor antagonists in this study had any obvious linear cor-
relation with their lipophilicity or PSA values (Supporting
Information, Figures S1 and S2).
“Left Arm” Optimization. Fixing the right arm as a piperidine
moiety, as in rimonabant, various ethers with different carbon
chain lengths were introduced on the left arm (Table 1). Exten-
sion of the trifluoromethylalkyl chain from three carbons (8a,
1.26 nM) to four atoms (11a, 0.32 nM) increased affinity by
about 4-fold. Reducing the level of fluorination on the terminal
carbon of the linear ether side chain from three atoms (8a, 1.26 nM)
to one atom (8b, 0.34 nM) also increased the affinity. By con-
trast, the analogue possessing a benzyl substituent on the left arm
(9, 6.28 nM) displayed the weakest affinity of the analogues
studied. The aforementioned modifications did not seem to
have a drastic effect on KRI, with all compounds giving values
around unity (0.80−1.09). As part of a strategy to increase PSA, a
sulfonyl-containing side chain was introduced. The ligand bear-
ing an n-propyl-sulfonyl moiety (11b) displayed a good affinity
of 0.28 nM and a rather low KRI value of 0.59. Monofluorinating
the terminal position led to no change in affinity (11c, 0.32 nM).
In contrast to the ether substituents, trifluorination resulted in an
almost 3-fold increase (11d, 0.11 nM) relative to the monofluoro
analogue. A slight increase in affinity was observed when the
linear sulfonyl side chain was extended from three carbon atoms
(11b, 0.28 nM) to four (11e, 0.18 nM). Combination of this
chain length with trifluoro-substitution, to give the side chain
found in the CB1 receptor agonist (−)-(R)-3-(2-hydroxymethylin-
danyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271),43,44
led to a very potent antagonist of the human CB1 receptor (11f,
62 pM). Branching the chain from n-butyl to i-pentyl did not
change the affinity (11g vs 11e) while introducing an additional
methyl group led to a decrease in affinity (11h, t-hex chain,
0.60 nM). None of these ligands had a KRI value higher than 1,
indicating their dissociation from the hCB1 receptor was faster
than CP55940. The analogue with the lowest KRI value (11b,
0.59) was selected for full-curve measurement (Figure 6, Table 4).
As expected, its residence time (78 min) was shorter than that of
CP55940 (114 min, see above) (Table 4). This result also serves
as evidence that a KRI value seems to reliably reflect the cor-
responding dissociation rate constant.
All the linear side chain antagonists had high affinities in the
nanomolar to subnanomolar range, with 11f (60 pM) as themost
potent derivative. However, from the perspective of drug−target
kinetic studies, despite giving a range of KRIs (0.59−1.09), none
of these antagonists showed a KRI value significantly higher
than 1, suggesting that none had longer residence times than
CP55940.
“Right Arm” Optimization. To explore the “right arm” of the
1,2-diarylimidazol-4-carboxamides, we chose to fix the “left arm”
as a trifluoropropyl sulfonyl moiety (11d) because this group
delivered high affinity (0.11 nM) and demonstrated a residence
time similar to CP55940 (KRI = 1.02, Table 1). Introducing a
hydroxyl at the 3-position of the piperidine ring yielded a ligand
with lower affinity and KRI value (14a,Ki = 0.27 nM, KRI = 0.71)
than 11d (Table 2).
Efforts then focused on a series of ligands bearing cyclohexyl
substituents instead of a piperidine. A carbocyclic analogue of
14a, bearing a trans-hydroxyl on the 3-position of the cyclohexyl
ring 14b (racemic), delivered an approximately 3-fold improve-
ment in affinity and a slightly larger KRI value relative to the
piperidine 14a (Table 2). Moving the hydroxyl to the 4-position
gave 4-hydroxycyclohexyl analogue (19) as a mixture of cis and
trans diastereoisomers in a ratio of 0.3:1 and resulted in an
approximately 4-fold reduction in affinity (0.37 nM), while the
KRI was unchanged (0.88); having a mixture does not allow any
further conclusions, though. Interestingly, the cis- and trans-2-
hydroxycyclohexyl antagonists (14d and 14c, respectively)
showed a substantial 10-fold difference in affinity, while their
KRI values were quite similar. The more potent cis-isomer (14d,
(+)) displayed an affinity of 27 pM and a KRI value close to unity.
Switching the 2-substituent of the cyclohexane ring to an amine
was detrimental, resulting in ligands with lower affinities. How-
ever, it is of note that the unsubstituted cis-amino group (22, (±),
0.52 nM) was less detrimental to affinity than a cis-dimethylamino
substituent (25, (±), 3.3 nM), while the dissociation rates were
very similar, as judged by their KRI values (Table 2). At this stage,
on the basis of affinity alone, 14d with an affinity of 27 pM seems
an even better lead than 11f with an affinity of 62 pM.
Last but not least, we found that by introducing an aromatic
moiety, the compounds retain affinity in the subnanomolar range
and, more importantly, their kinetic profiles were rather diverse.
The analogue which bears a 4-trifluoromethoxyphenyl sub-
stituent (14e) showed high affinity (0.22 nM) and its KRI value
was one of the highest measured (Table 2). Introduction of a
pyridine moiety was then studied. The 3-pyridyl analogues 14f
and 14g, bearing a 6-fluoro or trifluoromethyl group, respec-
tively, showed similar affinities (0.13 vs 0.31 nM, respectively),
although the latter had a much higher KRI value (1.12 vs 0.70,
respectively). This effect on KRI was increased further when the
position of the nitrogen atom in the ring was switched to give
the 5-substituted 2-pyridyl analogue (28, KRI = 1.39), which
displayed the highest KRI value of all the compounds presented
Figure 6. Competition association experiments with [3H]CP55940
binding to recombinant hCB1 receptors stably expressed on CHO cell
membranes (30 °C) in the absence or presence of unlabeled long residence
time compound 28 (8.22 nM, red, representative curve) or short residence
time compound 11b (12.72 nM, blue, representative curve). Data are
shown as mean values from one representative experiment. At least
three separate experiments each performed in duplicate.
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in this study. Finally, defluorinating this latter compound did not
change the affinity but gave rise to a marked reduction in KRI
(14h, Ki = 0.14 nM, KRI = 0.92).
The compounds with high (28) and low (11b and 14f) KRI
values were tested in a full competition association assay to deter-
mine their association and dissociation rate constants (Figure 6
and Table 4). According to the full curves, the compound with
KRI > 1 (28) displayed an “overshoot” in the competition asso-
ciation curve, indicating its slow dissociation and yielding the
longer residence time of 260 min, as compared to 114 min of the
radioligand. By contrast, the compounds with KRI < 1 produced
gradually ascending curves, suggesting faster dissociation and
consequently shorter residence times of 78 min (11b) and 62 min
(14f) (Figure 6, Table 4). Additionally, we determined their
affinities on the human CB2 receptor. From Table 1 and Sup-
porting Information, Table S1, they show that they all had higher
affinity for the human CB1 receptor, where approximately
12−125-fold selectivity over human CB2 receptors was observed.
Functional Assays. As mentioned above, the antagonism in
the [35S]GTPγS binding assay compares quite well with the
affinities derived from the [3H]CP55940 displacement studies
(Figure 2), while the KRI values of the compounds did not show
any meaningful correlation with the pIC50 values from the
GTPγS binding assay (Figure 5b). Because 28 showed slow
dissociation, we decided to study this compound further in a
more elaborate [35S]GTPγS binding experiment in which
its functional activity in the inhibition of CP55940 action was
characterized and compared with rimonabant. Pretreatment of
CHOK1 hCB1 receptor membranes with rimonabant for 1 h,
prior to stimulation by the CB1 receptor agonist CP55940 for
30 min, induced surmountable antagonism (a rightward shift of
the agonist curve with little suppression of the maximum effect)
as reported before.45 In the case of 28, insurmountable antagonism
was observed; the agonist concentration−effect curve was shifted
to the right with a concomitant decrease (∼50%) in its maximal
response (Figure 7). In both cases, inverse agonism by the com-
pounds alone (in the absence of CP55940) was also apparent
(negative values at Y-axis in Figure 7).
Computational Studies. Finally, we investigated the
ligand−receptor interactions using the recently disclosed X-ray
crystal structure of hCB1 in complex with 29 [4-(4-(1-(2,4-
dichlorophenyl)-4-methyl-3-(piperidin-1-ylcarbamoyl)-1H-pyr-
azol-5-yl)phenyl)but-3-ynyl nitrate, AM6538], crystal structure
code PDB 5TGZ.32 By docking 28 into the hCB1 receptor, it can
be seen that, like 29, it lies quite deep in the binding pocket of
hCB1 in the docked pose, immediately above the conserved
Trp3566.48 (Figures 8a,b). The main scaffold of the imidazole
core and the 2,4-dichlorophenyl ring forms a π−π interaction
with the side chains of Phe102N‑term and Phe1702.57, respectively
(Figure 8b). Unsurprisingly, and consistent with the SAR reported
in Table 1, the “left arm” of our ligand docks into the same place as
“Arm 2” of 29 in the crystal structure. This “left arm” extends into a
long, narrow, and highly lipophilic channel formed by helices III,
V, VI, and ECL2 (Figure 8a). By contrast, the “right arm” of our
ligands, which resemble “Arm 3” of 29, dock into an open cavity
formed by various hydrophobic amino acid residues,33 irrespec-
tive of whether a cyclohexyl, piperidine, or pyridine moiety is
present. In the case of a pyridine moiety (14e−14h and 28), the
crystal structure suggests that there may be a π−π stacking
interaction with His1782.65. Further support for the docked pose
of 28 comes from the higher resolutionX-ray structure of taranabant
bound to hCB1 (PDB 5U09)34 because both compounds share a
trifluoromethylpyridine moiety on their “right arm”.
Using the crystal structure of the hCB1−29 complex, we
performed WaterMap calculations to try and understand the
differences in residence times observed for the ligands studied,
with the hypothesis that unfavorable hydration might provide an
explanation.46−48 We focused on the pyridine ring substituents
on the “right arm”, and ligands 14f and 28 in particular, because
of their similar binding affinities but differing residence times.
The smaller of the two ligands (14f, −F substitution, relatively
short RT) was docked into the hCB1 receptor, and a WaterMap
was calculated for the complex. Around the F substituent, we found
unstable watermolecules (41, 69, 72, 81, and 88 in Figure 8c); these
water molecules are coined “unhappy” waters.49 By contrast,
ligand 28 was able to displace these water molecules with its
larger −CF3 substituent, a process which might raise the energy
of the transition state for dissociation. We postulate that this
destabilization of the transition state may contribute to the
prolonged residence time observed with this compound.
■ CONCLUSIONS
We have demonstrated that, in addition to affinity, knowledge of
binding kinetics is useful for selecting and developing new hCB1
receptor antagonists in the early phases of drug discovery. In the
specific case of the hCB1 receptor, a long residence time com-
pound may be beneficial for a peripherally selective antagonist.
We explored SAR and SKR parameters in a series of 1,2-diary-
limidazol-4-carboxamide derivatives by examining the influence
of substitutions at both “arms” of the molecules.
By introducing more polar linear sulfonyl side chains on the
“left arm”, affinity could be modulated, however, the KRI values
indicative for the compounds’ kinetic properties were less than or
similar to CP55940. Substitution of the “right arm” maintained
or increased affinity, and with the introduction of an aromatic
ring system, KRI values >1 were obtained. With a residence time
of 260 min, which is substantially longer than CP55940 (114min)
or rimonabant (14 min), 4-(2-(2,4-dichlorophenyl)-5-methyl-4-
((5-(trifluoromethyl)pyridin-2-yl)carbamoyl)-1H-imidazol-1-yl)-
phenyl-3,3,3-trifluoropropane-1-sulfonate (28) stood out from
the ligands studied. This slowly dissociating hCB1 receptor
antagonist also showed insurmountability in a functional GTPγS
binding assay. Using the recently resolved hCB1 crystal struc-
tures, we analyzed the putative interactions of 28with the receptor,
from which we speculate that displacement of “unhappy” water
Figure 7. CP55940-stimulated [35S]GTPγS binding to recombinant
hCB1 receptors stably expressed onCHO cell membranes (25 °C) in the
absence (black, representative curve) or presence of long-residence-time
compound 28 (red, representative curve) or rimonabant (blue,
representative curve). Compound 28 or rimonabant was preincubated
with the membranes for 1 h prior to the challenge of agonist.
[35S]GTPγS was subsequently added and incubated for another 0.5 h.
Plates were then filtered and the radioactivity counted. Curves were
fitted to a four parameter logistic dose−response equation. Data were
normalized according to the maximal response (100%) produced by
CP55940. At least three separate experiments each performed in
duplicate.
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Figure 8. (a) Docking of antagonist 28 into the binding site of the crystal structure of the CB1 receptor (PDB 5TGZ)
33 co-crystallized with 29 (not shown).
Compound 28 is represented by black sticks, and residueswithin 5Å of 28 are visualized as green sticks. The protein is represented by green ribbons, and relevant
binding site confinements are indicated by white-gray (hydrophobic), red (electronegative), and blue (electropositive) layers. Ligand and residues atoms color
code: yellow = sulfur, red = oxygen, blue = nitrogen, cyan = fluorine, white = hydrogen. (b) 2-D interaction map of 28 docking into the CB1 receptor
co-crystallizedwith 29 (PDB5TGZ),33 demonstratingπ−π stacking between imidazole core of 28 andPhe102N‑term, 2,4-dichlorophenyl ring andPhe1702.57, and
pyridine and His1782.65. (c) Docking of 14f and 28 into the binding site of the crystal structure of the CB1 receptor co-crystallized with 29 (PDB 5TGZ),33
showing the overlay of numbered consecutively hydration sites of 14f (colored spheres; for color code, see below) calculated by WaterMap. Hydration sites
shown as red and orange spheres represent “unstable”water molecules. White spheres symbolize “stable”water molecules, which should not be displaced by 14f
or 28. For the key hydration sites (41, 69, 72, 81, 88) surrounding the−F atomof 14f, calculatedΔG values (in kcal/mol)with respect to bulk solvent are shown.
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molecules may provide a plausible explanation for its slow dis-
sociation. Therefore, compound 28, or derivatives with similar
characteristics, may be a useful tool to test whether prolonged
blockade of the (peripheral) hCB1 receptor has a beneficial effect
on CB1 receptor related disorders such as obesity.
■ EXPERIMENTAL SECTION
Chemistry. All solvents and reagents were purchased from
commercial sources and were of analytical grade. Demineralized water
is simply referred to as water or H2O, as was used in all cases unless
stated otherwise (i.e., brine). Thin-layer chromatography (TLC) was
routinely consulted tomonitor the progress of reactions, using aluminum-
coated Merck silica gel F254 plates. Purification was performed on a
semipreparative high performance liquid chromatography (HPLC)with a
mass triggered fraction collector, a Shimadzu QP 8000 single quadrupole
mass spectrometer equipped with a 19 mm × 100 mm C8 column. The
mobile phase used was, if nothing else is stated, acetonitrile and buffer
(aqueous NH4OAc (0.1 M): acetonitrile 95:5). For isolation of isomers,
a Kromasil CN E9344 (250 mm × 20 mm i.d.) column was used. A mix-
ture of heptane/ethyl acetate/diethylamine 95:5:0.1 was used as mobile
phase (1 mL/min). Fraction collection was guided using a UV detector
(330 nm). Analytical purity of the final products was determined
by Waters Acquity I-class ultraperformance liquid chromatography
(UPLC) consisting of a binary solvent system, ultraviolet (UV) photo-
diode array (PDA) detector, column temperature control manager, and
sample manager modules, coupled with in-line and mass spectrometry
detection. The sample was injected onto, and separated by, a Waters
Acquity BEH (C18) 1.7 mm (150 mm × 3 mm) UPLC column
maintained at 40 °C and eluted with 0.1% ammonium hydroxide in
water (A) and acetonitrile (B) at a flow rate of 1 mL/min, using a linear
gradient. Initial conditions started at 3% B, which was increased to 97%
over 1.3 min and maintained for 0.2 min before returning to initial
conditions over 0.2 min prior to the next injection. Eluent contain-
ing UPLC-separated analytes then flowed via the UV PDA detector
scanning between 220 and 320 nmwavelengths at a resolution of 1.2 nm
sampling at 40 points/s into a Waters SQD single quadrupole mass
spectrometer (MS) fitted with an electrospray source. All MS analyses
were acquired for a total run time of 2 min, with mass scanning from 100
to 1000 μ in both positive and negative ion modes alternately, using
electrospray ionization (ESI). Typical MS settings included: capillary
voltage, 1 kV; cone voltage, 25 V; source temperature, 150 °C; desol-
vation temperature, 350 °C. The data were acquired via a PC running
MassLynx v4.1 in open access mode and processed and reported via
OpenLynx software application. For each sample, the purity is deter-
mined by integration of the UV absorption chromatogram. All final
compounds show a single peak and are at least 95% pure.
1H NMR measurements were performed on either a Varian Mercury
300 or a Varian Inova 500, operating at 1H frequencies of 300 and
500 MHz respectively at ambient temperature. Chemical shifts are
reported in parts per million (ppm), are designated by δ, and are
downfield to the internal standard tetramethylsilane (TMS) in CDCl3.
Coupling constants are reported in Hz and are designated as J. High-
resolution mass spectra were recorded on either a Micromass ZQ single
quadrupole or a Micromass LCZ single quadrupole mass spectrometer
both equipped with a pneumatically assisted electrospray interface
(LC-MS). Melting points were determined on a Reichert melting point
microscope and are uncorrected.
N-(4-(Benzyloxy)phenyl)-2,4-dichlorobenzamidine (2).Compound
1 (5.0 g, 21.2 mmol) was added dropwise to a solution of ethyl mag-
nesium bromide (44.5 mL, 1 M in THF, 44.5 mmol) in dry THF
(25 mL) under a nitrogen atmosphere. After stirring for 20 min, a
solution of 2,4-dichlorobenzonitrile (3.65 g, 21.2 mmol) in THF
(25 mL) was added. The reaction mixture was stirred for 20 h at rt.
Water (50mL)was carefully added. Extractionwith EtOAc (2× 100mL),
drying (Na2SO4), filtration, and evaporation to dryness afforded the crude
title compound (7.7 g, 98%).
Ethyl 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-
1H-imidazole-4-carboxylate (3). To a solution of compound 2
(6.88 g, 18.5 mmol) in THF (50 mL) was added potassium carbonate
(2.56 g, 18.5 mmol), and the suspension was stirred for 10 min. Ethyl-3-
bromo-2-oxobutanoate (4.65 g, 22.2 mmol) was added dropwise over
1 h, and the mixture was stirred for 66 h at rt. The solution was filtered
and evaporated to dryness. The residue was dissolved in AcOH and
refluxed for 1 h. The mixture was cooled to rt, water (100 mL) added,
and the product extracted with EtOAc (2 × 200 mL). The combined
organic phases were washed with saturated aqueous sodium hydrogen
carbonate, dried (Na2SO4), filtered, and concentrated in vacuo. Flash
chromatography (silica, 30−40% EtOAc in hexane) afforded the title
compound (5.75 g, 65%) as a pale-yellow solid. 1H NMR (CDCl3): δ
7.50−7.20 (m, 8H), 7.10−6.90 (m, 4H), 5.10 (s, 2H), 4.50 (q, 2H), 2.5
(s, 3H), 1.5 (t, 3H).
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imi-
dazole-4-carboxylic Acid (4). To a suspension of compound 3 (3.62 g,
7.5 mmol) in MeOH (60 mL) was added potassium hydroxide (4.05 g,
72 mmol) in water (20 mL) and the reaction mixture heated to reflux.
After 2 h the mixture was cooled to rt, acidified to pH ∼ 2 with HCl
(1 M), and extracted with ethyl acetate (2 × 200 mL). The combined
organic phases were dried (Na2SO4), filtered, and concentrated in vacuo
to give the crude title compound (3.38 g, 99%).
Ethyl 2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-1H-
imidazole-4-carboxylate (5). Compound 3 (4.82 g, 10 mmol) was
dissolved in HBr (33% in AcOH, 80 mL) and stirred overnight at rt with
exclusion of light. The solvents were evaporated and the residue
coevaporated with EtOH. The residue was dissolved in EtOH,HCl (4M
in dioxane, 5 mL), and MgSO4 were added, and the resulting mixture
heated under reflux for 2.5 h. The reaction mixture was cooled to rt,
filtered, and concentrated in vacuo. The residue was dissolved in EtOAc
and washed with water basified with triethylamine and then brine. The
organic layer was dried over Na2SO4 and concentrated in vacuo to give
the crude title compound (4.74 g) as a brown, viscous oil of sufficient
purity for the next step.
Ethyl 2-(2,4-Dichlorophenyl)-5-methyl-1-(4-(3,3,3-trifluoropropo-
xy)phenyl)-1H-imidazole-4-carboxylate (6a).A solution of compound
5 (978 mg, 2.5 mmol), 3,3,3-trifluoro-1-propanol (428 mg, 3.75 mmol),
and triphenylphosphine (984 mg, 3.75 mmol) in anhydrous THF
(12mL) were treated with DEAD (40% in toluene, 1.72mL, 3.75mmol).
The resulting mixture was stirred at rt for 30 h then heated to 50 °C
overnight. After cooling to rt, additional 3,3,3-trifluoro-1-propanol
(428 mg, 3.75 mmol) and triphenylphosphine (984 mg, 3.75 mmol)
were added, followed by di-tert-butylazodicarboxylate (863 mg,
3.75 mmol) and the resulting mixture stirred at rt overnight. Again,
additional 3,3,3-trifluoro-1-propanol (428 mg, 3.75 mmol) and triphenyl-
phosphine (984 mg, 3.75 mmol) were added, followed by di-tert-butyl
azodicarboxylate (863 mg, 3.75 mmol), and the resulting mixture was
stirred at rt overnight. The mixture was concentrated in vacuo and the
residue purified by column chromatography (silica gel, 10−50% EtOAc in
hexanes) to yield the title compound (880 mg, 68%) as a yellowish foam
of sufficient purity for the next transformation. 1H NMR (500 MHz,
CDCl3) δ 7.22−7.16 (m, 3H), 7.01 (d, J = 8.7 Hz, 2H), 6.83 (d, J =
8.7 Hz, 2H), 4.40 (q, J = 7.1 Hz, 2H), 4.22−4.10 (m, 2H), 2.66−2.54
(m, 2H), 2.40 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H).
Ethyl 2-(2,4-Dichlorophenyl)-1-(4-(3-fluoropropoxy)phenyl)-5-
methyl-1H-imidazole-4-carboxylate (6b). A solution of compound 5
(978 mg, 2.5 mmol), 3-fluoropropan-1-ol (293 mg, 3.75 mmol), and tri-
phenylphosphine (984 mg, 3.75 mmol) in anhydrous THF (9 mL) were
treated with DEAD (40% solution in toluene, 1.72mL, 3.75 mmol). The
resulting mixture was stirred at rt overnight. The residue was purified by
column chromatography (silica gel, 20−40% EtOAc in hexanes). The
product containing fractions were combined and concentrated in vacuo.
The residue was dissolved in CH2Cl2, then an equal amount of hexane
was added. The resulting solid was filtered off, and the filtrate concen-
trated in vacuo to yield the title compound (1.07 g, 85%) as a colorless
foam of ca. 90% purity, which was used in the next transformation
without further purification. 1H NMR (500 MHz, CDCl3) δ 7.35−7.20
(m, 3H), 7.03 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 4.73−4.60
(m, 2H), 4.44 (q, J = 7.1 Hz, 2H), 4.11−4.07 (m, 2H), 2.44 (s, 3H),
2.24−2.13 (m, 2H), 1.44 (t, J = 7.1 Hz, 3H).
2-(2,4-Dichlorophenyl)-5-methyl-1-(4-(3,3,3-trifluoropropoxy)-
phenyl)-1H-imidazole-4-carboxylic Acid (7a). A stirred solution of
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compound 6a (880 mg, 1.72 mmol), in a mixture of THF (15 mL) and
EtOH (15 mL), was treated with KOH (1.07 g, 19 mmol), dissolved in
water (10 mL), and the resulting mixture stirred at 50 °C. After 3 h
30 min, the reaction mixture was cooled to rt then concentrated in
vacuo. The residue was partitioned between CH2Cl2 and HCl (1 M)
and, after phase separation, the aqueous layer was extracted two more
times with CH2Cl2. The combined organic extracts were dried over
MgSO4 and concentrated in vacuo to give the title compound (714 mg,
90%) as a yellowish foam. 1H NMR (500 MHz, CDCl3) δ 7.32−7.18
(m, 3H), 7.00 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 4.18−4.14
(m, 2H), 2.66−2.55 (m, 2H), 2.42 (s, 3H).
2-(2,4-Dichlorophenyl)-1-(4-(3-fluoropropoxy)phenyl)-5-methyl-
1H-imidazole-4-carboxylic Acid (7b). A solution of compound 6b
(1.07 g, 2.13 mmol, ca. 90% pure), in a mixture of THF (20 mL) and
EtOH (20 mL), was treated with KOH (1.40 g, 25 mmol) dissolved in
water (10 mL) and the resulting mixture stirred at 50 °C. After 3 h
30 min, the reaction mixture was cooled to rt then concentrated in
vacuo. The residue was partitioned between CH2Cl2 and HCl (1 M)
and, after phase separation, the aqueous layer extracted with CH2Cl2 and
twice with EtOAc. The combined organic extracts were dried over
MgSO4 and concentrated in vacuo to give the title compound (856 mg,
95%) as a yellowish foam which was sufficiently pure for the next step.
1H NMR (500 MHz, CDCl3) δ 7.35−7.22 (m, 3H), 7.04 (d, J = 8.7 Hz,
2H), 6.88 (d, J = 8.7 Hz, 2H), 4.72−4.60 (m, 2H), 4.12−4.09 (m, 2H),
2.46 (s, 3H), 2.25−2.14 (m, 2H).
2-(2,4-Dichlorophenyl)-5-methyl-N-(piperidin-1-yl)-1-(4-(3,3,3-
trifluoropropoxy)phenyl)-1H-imidazole-4-carboxamide (8a). A solu-
tion of compound 7a (643 mg, 1.4 mmol) in CH2Cl2 (10 mL) was
treated with oxalyl chloride (200 μL, 2.36 mmol), followed by 10 μL of
DMF. The resulting mixture was stirred for 90 min at rt, then concen-
trated in vacuo. The residue was dried under vacuum as a yellowish foam
which was used without further purification. Subsequently, to a mixture
of piperidin-1-amine hydrochloride (0.3 mmol) and pyridine (100 μL)
in CH2Cl2 (1 mL) was added a portion of crude intermediate (2-(2,4-
dichlorophenyl)-5-methyl-1-(4-(3,3,3-trifluoropropoxy)phenyl)-1H-
imidazole-4-carbonyl chloride (96 mg, 0.2 mmol)) in CH2Cl2 (1 mL),
and the resulting mixture stirred at rt for 2 h 30 min. The reaction
mixture was washed with saturated aqueous NaHCO3 (2 mL) and, after
phase separation, filtered through a phase separator. The solvents were
evaporated and the residue purified by preparative HPLC eluting on a
reverse-phase column (5−100% acetonitrile in aqueous NH4OAc
(0.1 M)) to give the title compound (45 mg, 41%) as a colorless solid.
1H NMR (500 MHz, CDCl3) δ 7.90 (s, 1H), 7.35 (d, J = 1.9 Hz, 3H),
7.29 (d, J = 8.3 Hz, 1H), 7.23 (dd, J = 1.9, 8.3 Hz, 1H), 7.03 (d, J =
8.9 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 2.94−2.81
(m, 4H), 2.69−2.60 (m, 2H), 2.47 (s, 3H), 1.82−1.73 (m, 4H),
1.49−1.41 (m, 2H). HRMS Calcd for [C25H25Cl2F3N4O2 + H]:
541.1385. Found: 541.1366. HPLC: 100%.
2-(2,4-Dichlorophenyl)-1-(4-(3-fluoropropoxy)phenyl)-5-methyl-
N-(piperidin-1-yl)-1H-imidazole-4-carboxamide (8b). A solution of
compound 7b (732 mg, 1.55 mmol) in CH2Cl2 (20 mL) was treated
with oxalyl chloride (200 μL, 2.36 mmol), followed by DMF (10 μL).
The resulting mixture was stirred for 90 min at rt, then concentrated in
vacuo. The residue was dried under vacuum as a yellowish foam which
was used without further purification. Subsequently, to a mixture of
piperidin-1-amine hydrochloride (0.39 mmol) and pyridine (100 μL) in
CH2Cl2 (2 mL) was added a portion of crude 2-(2,4-dichlorophenyl)-1-
(4-(3-fluoropropoxy)phenyl)-5-methyl-1H-imidazole-4-carbonyl chlor-
ide (115 mg, 0.26 mmol) in CH2Cl2 (2 mL), and the resulting mixture
was stirred at rt for 2 h. The reaction mixture was washed with saturated
aqueous NaHCO3 (2 mL) and, after phase separation, filtered through a
phase separator. The solvents were evaporated and the residue purified
by preparative HPLC eluting on a reverse-phase column (5−100%
CH3CN in aqueous NH4OAc (0.1 M)) to give the title compound
(74mg, 56%) as a colorless solid. 1HNMR (500MHz, CDCl3) δ 7.90 (s,
1H), 7.35 (d, J = 2.0 Hz, 1H), 7.28 (d, J = 8.2 Hz, 1H), 7.23 (dd, J = 2.0,
8.2 Hz, 1H), 7.01 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 8.9 Hz, 2H), 4.66 (dt,
J = 5.7, 47.0 Hz, 2H), 4.09 (t, J = 6.1 Hz, 2H), 2.95−2.82 (m, 4H), 2.47
(s, 3H), 2.25−2.13 (m, 2H), 1.81−1.73 (m, 4H), 1.49−1.40 (m, 2H).
HRMS Calcd for [C25H27Cl2FN4O2 + H]: 505.1573. Found: 505.1572.
HPLC: 100%.
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(pi-
peridin-1-yl)-1H-imidazole-4-carboxamide (9). To a solution of
compound 4 (3.38 g, 7.5 mmol) in CH2Cl2 (60 mL) were added
3 drops of DMF, followed by oxalyl chloride (1.3 mL, 14.9 mmol). The
mixture was refluxed for 2 h, then cooled to rt and evaporated to dryness.
The residue was dissolved in CH2Cl2 (50 mL) and cooled to 0 °C.
Triethylamine (2.1 mL, 14.9 mmol) was added, followed by piperidin-1-
amine (0.9 mL, 8.2 mmol), and the mixture stirred at rt for 2 h. Water
(300 mL) was added, and the mixture extracted with CH2Cl2 (3 ×
100 mL). The organic extracts were dried (Na2SO4), filtered, and
concentrated in vacuo. Flash chromatography (silica, 66−100% EtOAc
in hexane) afforded the title compound (2.94 g, 74%) as a white solid.
1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.3 Hz, 1H), 7.42−7.32
(m, 7H), 7.29 (dd, J = 1.9, 8.3 Hz, 1H), 7.24 (d, J = 9.0 Hz, 2H), 6.98
(d, J = 9.0 Hz, 2H), 5.04 (s, 2H), 4.05−3.52 (m, 4H), 2.54 (s, 3H),
2.29−2.16 (m, 4H), 1.78−1.57 (m, 2H). HRMS Calcd for
[C29H28Cl2N4O2 + H]: 535.1667. Found: 535.1667. HPLC: 96.9%.
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-N-(piperi-
din-1-yl)-1H-imidazole-4-carboxamide (10). A solution of compound
9 (2.78 g, 5.2 mmol) in CH2Cl2 (80mL) was cooled to 0 °C then treated
dropwise with boron tribromide (1 M in CH2Cl2, 10.4 mL, 10.4 mmol).
The reaction mixture was stirred at rt for 1 h then treated with water
(200 mL). The mixture was extracted with EtOAc (3 × 200 mL). The
combined organic phases were dried (Na2SO4), filtered, and concen-
trated in vacuo. Flash chromatography (silica, 75−100% EtOAc in
hexane) afforded the title compound (1.34 g, 58%) as a white solid. 1H
NMR (400 MHz, CDCl3) δ 8.66 (br s, 1H), 7.94 (br s, 1H), 7.31 (d, J =
1.9 Hz, 1H), 7.23 (d, J = 8.3 Hz, 1H), 7.18 (dd, J = 1.9, 8.3 Hz, 1H),
6.92−6.85 (m, 4H), 2.90−2.67 (m, 4H), 2.43 (s, 3H), 1.69−1.56 (m,
4H), 1.43−1.30 (m, 2H).
2-(2,4-Dichlorophenyl)-5-methyl-N-(piperidin-1-yl)-1-(4-(4,4,4-tri-
fluorobutoxy)-phenyl)-1H-imidazole-4-carboxamide (11a). A sus-
pension of compound 10 (351 mg, 0.79 mmol) and K2CO3 (218 mg,
1.58 mmol) in acetone (50 mL) was treated dropwise with 1-iodo-4,4,4-
trifluorobutane (376mg, 1.58mmol). The reactionmixture was refluxed
overnight then cooled, filtered, and concentrated in vacuo. Flash
chromatography (silica, hexane:EtOAc 1:2) afforded the title compound
(200 mg, 46%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.91
(br s, 1H), 7.32 (d, J = 1.9 Hz, 1H), 7.27 (d, J = 8.3 Hz, 1H), 7.21 (dd, J =
2.0, 8.3 Hz, 1H), 7.00 (d, J = 8.9 Hz, 2H), 6.83 (d, J = 8.9 Hz, 2H), 3.99
(t, J = 6.0 Hz, 2H), 3.13−2.67 (m, 4H), 2.45 (s, 3H), 2.38−2.23
(m, 2H), 2.10−2.00 (m, 2H), 1.84−1.71 (m, 4H), 1.50−1.38 (m, 2H).
MS m/z 578 (M + Na). HRMS Calcd for [C26H27Cl2F3N4O2 + H]:
555.1541. Found: 555.1504. HPLC: 100%.
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-
1H-imidazol-1-yl)phenyl propane-1-sulfonate (11b). A solution of
compound 10 (320 mg, 0.72 mmol) in CH2Cl2 (10 mL) was cooled to
0 °C. Et3N (100 μL, 0.72 mmol) was added, followed by 1-prop-
anesulfonyl chloride (81 μL, 0.72 mmol), and the reaction mixture was
stirred at room temperature overnight. Water was added, the mixture
extracted with CH2Cl2 (3 × 20 mL), dried (Na2SO4), filtered, and
concentrated. Flash chromatography (silica, hexane:EtOAc 1:2)
afforded the title compound (220 mg, 56%) as a white solid. 1H NMR
(400 MHz, CDCl3) δ 7.82 (br s, 1H), 7.29−7.15 (m, 5H), 7.10−7.03
(m, 2H), 3.23−3.14 (m, 2H), 2.90−2.70 (m, 4H), 2.42 (s, 3H),
2.01−1.88 (m, 2H), 1.75−1.65 (m, 4H), 1.41−1.31 (m, 2H), 1.06 (t, J =
7.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.8, 149.0, 142.3, 136.8,
135.3, 135.0, 133.8, 133.4, 130.6, 129.9, 129.1, 128.2, 127.4, 123.1, 57.2,
52.9, 25.4, 23.3, 17.5, 13.0, 10.9. HRMS Calcd for [C25H28Cl2N4O4S +
H]: 551.1287. Found: 551.1313. HPLC: 100%.
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-
1H-imidazol-1-yl)phenyl-3-fluoropropane-1-sulfonate (11c). A sus-
pension of compound 10 (200 mg, 0.45 mmol) in dry CH2Cl2 (3 mL)
was treated with Et3N (45 mg, 0.45 mmol) at rt. The resulting mixture
was cooled to−78 °C, and 3-fluoropropane-1-sulfonyl chloride (72 mg,
0.45 mmol) in dry CH2Cl2 (0.5 mL) was added dropwise. After 1 h
40 min at −78 °C was added 3-fluoropropane-1-sulfonyl chloride
(72 mg, 0.45 mmol) and after a total of 4 h 40 min was added Et3N
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(55 mg, 0.54 mmol). The reaction was allowed to reach rt overnight.
It was then cooled to 0 °C and Et3N (55 mg, 0.54 mmol) was added,
followed by 3-fluoropropane-1-sulfonyl chloride (72 mg, 0.45 mmol)
after a total of 19 h. After 1 h, the reaction mixture was washed with
water and concentrated in vacuo. The product was purified by HPLC
(30−100% CH3CN in aqueous NH4OAc (0.1 M) over 40 min) to yield
the title compound as a white solid (160 mg, 63%). 1HNMR (400MHz,
CDCl3) δ 7.88 (br s, 1H), 7.39−7.17 (m, 5H), 7.11 (d, J = 8.8 Hz, 2H),
4.58 (dt, J = 5.5, 46.8 Hz, 2H), 3.53−3.33 (m, 2H), 2.92−2.71 (m, 4H),
2.45 (s, 3H), 2.40−2.23 (m, 2H), 1.83−1.62 (m, 4H), 1.46−1.33 (m,
2H). HRMS Calcd for [C25H27Cl2FN4O4S + H]: 569.119. Found:
569.1192. HPLC: 100%.
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-
1H-imidazol-1-yl)phenyl 3,3,3-trifluoropropane-1-sulfonate Metha-
nesulfonic Acid Salt (11d). A solution of compound 10 (0.89 g,
2.00 mmol) in CH2Cl2 (20 mL) was cooled to 0 °C then treated with
Et3N (0.35 mL, 2.4 mmol), followed by 3,3,3-trifluoropropanesulfonyl
chloride (prepared by an analogous method to that described inWO00/
010968 for the butyl homologue) (0.35 mL, 2.40 mmol). The reaction
mixture was stirred at rt overnight. TLC showed remaining starting
material, and so another portion of Et3N and 3,3,3-trifluoropropane-
sulfonyl chloride was added and the reaction mixture stirred for
additional 2 h. Water was added, and the product was extracted with
CH2Cl2, dried (Na2SO4), filtered, and concentrated in vacuo. Flash
chromatography (33−100% EtOAc in hexane) followed by recrystal-
lization (hexane:EtOAc) afforded the title compound (700 mg, 59%) as
a colorless solid. 1HNMR (400MHz, CDCl3) δ 7.92 (s, 1H), 7.34−7.24
(m, 5H), 7.20−7.13 (m, 2H), 3.54−3.48 (m, 2H), 3.00−2.82 (m, 4H),
2.84−2.73 (m, 2H), 2.50 (s, 3 H), 1.83−1.72 (m, 4 H), 1.49−1.39 (m,
2H). HRMS Calcd for [C26H29Cl2F3N4O7S2 + H]: 605.1004. Found:
605.1012. HPLC: 100%.
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-
1H-imidazol-1-yl)phenyl butane-1-sulfonate (11e). A solution of
compound 10 (320 mg, 0.72 mmol) in CH2Cl2 (10 mL) was cooled to
0 °C. Et3N (100 μL, 0.72 mmol) was added followed by 1-buta-
nesulfonyl chloride (93 μL, 0.72 mmol), and the reaction mixture was
stirred at rt overnight. Water was added, and the mixture extracted with
CH2Cl2 (3 × 20 mL), dried (Na2SO4), filtered, and concentrated in
vacuo. Flash chromatography (silica, hexane:EtOAc 1:2) afforded the
title compound (230 mg, 57%) as a white solid. 1H NMR (400 MHz,
CDCl3) δ 7.82 (br s, 1H), 7.27−7.16 (m, 5H), 7.09−7.04 (m, 2H),
3.23−3.17 (m, 2H), 2.92−2.68 (m, 4H), 2.42 (s, 3H), 1.93−1.84
(m, 2H), 1.74−1.66 (m, 4H), 1.50−1.40 (m, 2H), 1.40−1.33 (m, 2H),
0.91 (t, J = 7.4 Hz, 3H). MS m/z 588 (M + Na). HRMS Calcd for
[C26H30Cl2N4O4S + H]: 565.1443. Found: 565.1450. HPLC: 100%.
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-
1H-imidazol-1-yl)-phenyl-4,4,4-trifluorobutane-1-sulfonate (11f).
A solution of compound 10 (0.49 g, 1.20 mmol) in CH2Cl2 (20 mL)
was cooled to 0 °C and treated with Et3N (0.67mL, 4.8 mmol), followed
by 4,4,4-trifluorobutane-1-sulfonyl chloride (prepared as described in
WO00/010968) (0.38 g, 1.80 mmol). The reaction mixture was stirred
at rt for 3 h. TLC showed remaining starting material, so another portion
of Et3N and 4,4,4-trifluorobutane-1-sulfonyl chloride was added and the
reaction mixture stirred overnight. Water was added, then the mixture
was extracted with CH2Cl2. The organic extracts were dried (Na2SO4),
filtered, and concentrated in vacuo. Flash chromatography (33−100%
EtOAc in hexane) followed by recrystallization (hexane:EtOAc)
afforded the title compound (0.45 g, 61%) as a colorless solid. 1H
NMR (400MHz, CDCl3) δ 7.92 (br s, 1H), 7.34−7.22 (m, 5H), 7.15 (d,
J = 8.7 Hz, 2H), 3.38 (t, J = 7.3 Hz, 2H), 3.12−2.74 (m, 4H), 2.49 (s,
3H), 2.43−2.32 (m, 2H), 2.32−2.22 (m, 2H), 1.82−1.74 (m, 4H),
1.50−1.40 (m, 2H). HRMS Calcd for [C26H27Cl2F3N4O4S + H]:
619.1160. Found: 619.1148. HPLC: 96.9%.
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-
1H-imidazol-1-yl)phenyl 3-methylbutane-1-sulfonate (11g). A sol-
ution of compound 10 (50 mg, 0.11 mmol) in CH2Cl2 (3 mL) was
cooled to 0 °C then treated with Et3N (20 μL, 0.13mmol). The resulting
mixture was cooled to−78 °C, then 3-methylbutane-1-sulfonyl chloride
(23 mg, 0.13 mmol) carefully added. The reaction was stirred at−78 °C
for 1.5 h. Water was added, then the mixture was extracted with CH2Cl2.
The organic extracts were dried, filtered, and concentrated in vacuo to
give a residue which was purified byHPLC to deliver the title compound
(46 mg, 71%) as a solid. 1H NMR (400 MHz, CDCl3) δ 7.86 (s, 1H),
7.31−7.20 (m, 5H), 7.14−7.08 (m, 2H), 3.27−3.20 (m, 2H), 2.89−2.76
(m, 4H), 2.46 (s, 3H), 1.87−1.79 (m, 2H), 1.78−1.68 (m, 5H), 1.44−1.36
(m, 2H), 0.93 (d, J = 6.5Hz, 6H).HRMSCalcd for [C26H27Cl2F3N4O4S +
H]: 579.1600. Found: 579.1584. HPLC: 100%.
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-
1H-imidazol-1-yl)phenyl-3,3-dimethylbutane-1-sulfonate (11h).
A solution of compound 10 (50 mg, 0.11 mmol) in CH2Cl2 (3 mL)
was cooled to 0 °C and treated with Et3N (20 μL, 0.13 mmol). The
resulting mixture was cooled to −78 °C, and 3,3-dimethylbutane-1-
sulfonyl chloride (25 mg, 0.13 mmol) was carefully added. The reaction
was stirred at −78 °C for 2 h. Water was added, then the mixture
extracted with CH2Cl2. The organic extracts were dried, filtered, and
concentrated in vacuo to give a residue which was purified by preparative
HPLC to deliver the title compound (46 mg, 69%) as a solid. 1H NMR
(400 MHz, CDCl3) δ 7.85 (s, 1H), 7.32−7.17 (m, 5H), 7.11−7.09 (d,
J = 8.7 Hz, 2H), 3.26−3.15 (m, 2H), 2.92−2.74 (m, 4H), 2.46 (s, 3H),
1.87−1.78 (m, 2H), 1.77−1.68 (m, 5H), 1.46−1.34 (m, 2H), 0.92
(s, 9H). HRMS Calcd for [C28H34Cl2N4O4S + H]: 593.1756. Found:
593.1755. HPLC: 100%.
Racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-(3-hy-
droxypiperidin-1-yl)-5-methyl-1H-imidazole-4-carboxamide (12a).
Compound 4 (752 mg, 1.66 mmol) and SOCl2 (33.2 mmol) were
mixed, and the resulting mixture was refluxed for 1.5 h. Excess SOCl2
was removed under reduced pressure and the residue was azeotroped
with toluene. 3-Hydroxy-1-aminopiperidine (6.64 mmol) was mixed
with CH2Cl2 (15 mL) and THF (2 mL) and Et3N (13.28 mmol). The
mixture was cooled to −20 °C under a nitrogen atmosphere. A THF
(5 mL) mixture of the acid chloride from above was added dropwise
during 20 min. The resulting mixture was allowed to slowly warm to rt
and stirred overnight. Aqueous NaOH (1M, 5 mL) and EtOH (15 mL)
were added, and the mixture was heated to 40 °C for 15 min. The
reaction mixture was then diluted to 50 mL with CH2Cl2 and washed
with water (2 × 20 mL) and brine (20 mL). The organic layer was dried
(MgSO4), filtered, and concentrated in vacuo. The residue was purified
by flash chromatography (8% EtOH in CH2Cl2) and then by reverse
phase HPLC (Kromasil C8, 60% CH3CN in aqueous NH4OAc
(0.1 M)). The product fraction was concentrated in vacuo and then
dissolved in CH2Cl2 and washed with water several times and then brine.
The organic layer was dried (MgSO4), filtered, and concentrated in
vacuo to give the title compound (160 mg, 17% yield). 1H NMR
(400 MHz, CDCl3) δ 7.99 (s, 1H), 7.33−7.19 (m, 6H), 7.18−7.07
(m, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 5.18 (s, 1H),
4.92 (s, 2H), 3.94−3.85 (m, 1H), 3.06−2.97 (m, 1H), 2.85−2.66 (m,
3H), 2.34 (s, 3H), 1.87−1.77 (m, 1H), 1.63−1.50 (m, 2H), 1.46−1.34
(m, 1H); MS m/z 551 (M + H).
Racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-(3-hy-
droxycyclohexyl)-5-methyl-1H-imidazole-4-carboxamide (12b).
A suspension of compound 4 (2.00 g, 4.41 mmol) in CH2Cl2 (50 mL)
was treated with oxalyl chloride (2.80 g, 22.1 mmol) at rt, followed by
one drop of DMF. The mixture was stirred at rt for 15 min, after which
the solvent was removed in vacuo. The acid chloride was suspended in
CH2Cl2 (10 mL) and added dropwise to a mixture of 3-aminocyclo-
hexanol (610 mg, 5.29 mmol), aqueous NaOH (1 M, 30 mL), and
CH2Cl2 (30 mL). After stirring at rt for 2 h, adding more 3-aminocyclo-
hexanol after 1 h 25 min (67 mg, 0.58 mmol) and 1 h 45 min (58 mg,
0.50 mmol), water, and CH2Cl2 were added and the phases separated.
The organic phase was washed with aqueous HCl (10%) and brine, then
dried (MgSO4), filtered, and concentrated in vacuo to yield the crude
title compound (2.79 g). 1H NMR (400 MHz, CDCl3) δ 7.40−7.16
(m, 8H), 7.03−6.88 (m, 4H), 5.01 (s, 2H), 4.44−4.32 (m, 0.5H),
4.18−4.11 (m, 0.5 H), 4.06−3.94 (m, 0.5 H), 3.76−3.66 (m, 0.5 H),
2.46 (s, 3H), 2.03−1.10 (m, 8H). MS m/z 550 (M+H).
Racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-
((trans)-2-hydroxycyclohexyl)-5-methyl-1H-imidazole-4-carboxa-
mide (12c). A suspension of compound 4 (2.00 g, 4.41 mmol) in
CH2Cl2 (100 mL) was treated with oxalyl chloride (2.80 g, 22.1 mmol)
at rt, followed by one drop of DMF. The mixture was stirred at rt for
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35 min, after which the mixture was concentrated in vacuo. The acid
chloride was suspended in CH2Cl2 (10 mL) and added dropwise
to a mixture of trans-2-aminocyclohexanol hydrochloride (802 mg,
5.29 mmol), aqueous NaOH (1M, 30 mL), and CH2Cl2 (30 mL). After
stirring at rt for 2 h, water/CH2Cl2 were added, and the phases were
separated. The organic phase was washed with aqueous HCl (10%) and
brine, dried (MgSO4), filtered, and concentrated in vacuo to yield the
crude title compound (2.69 g). 1H NMR (400 MHz, CDCl3) δ 7.94
(s, 1H), 7.37−7.25 (m, 6H), 7.23−7.17 (m, 2H), 6.97 (d, J = 8.6 Hz,
2H), 6.89 (d, J = 8.6 Hz, 2H), 5.23 (s, 1H), 4.98 (s, 2H), 3.80−3.62
(m, 1H), 3.59−3.42 (m, 1H), 2.42 (s, 3H), 2.14−1.93 (m, 2H),
1.75−1.59 (m, 2H), 1.39−1.14 (m, 4H). MS m/z 550 (M + H).
Racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-((cis)-
2-hydroxycyclohexyl)-5-methyl-1H-imidazole-4-carboxamide (12d).
A suspension of compound 4 (2.00 g, 4.41 mmol) in CH2Cl2 (100 mL)
was treated with oxalyl chloride (2.85 g, 22.5 mmol) at rt, followed by
one drop of DMF. The mixture was stirred at rt for 20 min, after which
the solvents were evaporated under reduced pressure. The acid chloride
was suspended in CH2Cl2 (10 mL) and added dropwise to a mixture of
cis-2-aminocyclohexanol hydrochloride (816 mg, 5.38 mmol), aqueous
NaOH (1M, 30 mL) and CH2Cl2 (30 mL). After stirring at rt for 2 h,
water was added and the phases were separated. The organic phase was
washed with aqueous HCl (0.1 M) and brine, dried (MgSO4), filtered,
and concentrated in vacuo to yield the title compound (2.40 g, 99%).
1HNMR (400 MHz, CDCl3) δ 7.45 (d, J = 7.8 Hz, 1H), 7.41−7.16
(m, 8H), 6.98 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 5.01 (s, 2H),
4.16−4.08 (m, 1H), 4.03−3.96 (m, 1H), 2.89 (br s, 1H), 2.43 (s, 3H),
1.83−1.54 (m, 6H), 1.47−1.32 (m, 2H). MS m/z 550 (M + H).
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(4-
(trifluoromethoxy)phenyl)-1H-imidazole-4-carboxamide (12e).
A suspension of compound 4 (1.00 g, 2.21 mmol) in CH2Cl2 (15 mL)
was treated with oxalyl chloride (1.40 g, 11.0 mmol) at rt, followed by
one drop of DMF. The mixture was stirred at rt for 15 min, after which
the solvents were evaporated under reduced pressure. A mixture of
4-trifluoromethoxy-phenylamine (469 mg, 2.65 mmol), Et3N (313 mg,
3.09 mmol), and CH2Cl2 (5 mL) was added dropwise to the acid
chloride suspended in CH2Cl2 (15 mL). The reaction mixture was stirred
at rt for 2 h and 10 min. CH2Cl2 was added, and the resulting mix-
ture was washed with aqueous HCl (10%) and brine, dried (MgSO4),
filtered, and evaporated to yield the crude title compound (1.42 g). 1H
NMR (400 MHz, CDCl3) δ 9.37 (br s, 1H), 7.76−7.74 (m, 2H),
7.39−7.16 (m, 10H), 7.05−6.93 (m, 4H), 5.03 (s, 2H), 2.50 (s, 3H). MS
m/z 612 (M + H).
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-(6-fluoropyri-
din-3-yl)-5-methyl-1H-imidazole-4-carboxamide (12f). A suspension
of compound 4 (1.00 g, 2.21mmol) in CH2Cl2 (15mL)was treated with
oxalyl chloride (1.40 g, 11.0 mmol) at rt, followed by one drop of DMF.
The mixture was stirred at rt for 5 min after which the solvents were
removed in vacuo. The acid chloride was suspended in CH2Cl2 (8 mL)
then treated dropwise with a mixture of 6-fluoro-pyridin-3-ylamine
(297 mg, 2.65 mmol), Et3N (313 mg, 3.09 mmol), and CH2Cl2 (7 mL).
Stirring was continued at rt for 75 min, after which CH2Cl2 was added
and the resulting mixture washed with aqueous HCl (10%) and brine.
The organic extracts were dried (MgSO4), filtered, and concentrated in
vacuo to yield the crude title compound (1.19 g). 1H NMR (400 MHz,
CDCl3) δ 9.24 (s, 1H), 8.39−8.33 (m, 2H), 7.39−6.89 (m, 3H), 5.02
(s, 2H), 2.49 (s, 3H). MS m/z 547 (M + H).
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(6-
(trifluoromethyl)pyridin-3-yl)-1H-imidazole-4-carboxamide (12g).
A suspension of compound 4 (1.00 g, 2.21 mmol) in CH2Cl2 (15 mL)
was treated with oxalyl chloride (1.40 g, 11.03 mmol) at rt, followed by
one drop of DMF. Themixture was stirred at rt for 5 min, after which the
solvents were removed in vacuo. The acid chloride was suspended in
CH2Cl2 (8 mL) then treated dropwise with a solution of 6-trifluoro-
methyl-pyridin-3-ylamine (407 mg, 2.51 mmol) and Et3N (360 mg,
3.56 mmol) in CH2Cl2 (7 mL). The reaction mixture was stirred at rt
for 1.5 h then diluted with CH2Cl2 and washed with aqueous HCl
(10% w/w) and brine. The organic extracts were dried (MgSO4), filtered,
and concentrated in vacuo to yield the crude title product (1.32 g). 1H
NMR (400 MHz, CDCl3) δ 9.50 (s, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.55
(dd, J = 2.0, 8.6 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.40−7.21 (m, 7H),
7.06−6.89 (m, 5H), 5.03 (s, 2H), 2.50 (s, 3H). MS m/z 597 (M + H).
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(5-
methylpyridin-2-yl)-1H-imidazole-4-carboxamide (12h). A suspen-
sion of compound 4 (3.00 g, 6.62 mmol) in CH2Cl2 (70mL) was treated
with oxalyl chloride (4.20 g, 33.1 mmol) at rt, followed by one drop of
DMF. The mixture was stirred at rt for 5 min, after which the solvents
were evaporated under reduced pressure. Amixture of 5-methyl-pyridin-
2-ylamine (816 mg, 7.54 mmol), Et3N (890 mg, 8.80 mmol), and
CH2Cl2 (20 mL) was added dropwise to the acid chloride suspended in
CH2Cl2 (20 mL). The reaction mixture was stirred at rt for 30 min.
CH2Cl2 was added, and the resulting mixture was washed with aqueous
HCl (10%) and brine, dried (MgSO4), filtered, and evaporated. The
residue was purified by flash chromatography (20−30% EtOAc in
heptane) to yield the title compound as a white solid (980 mg, 27%). 1H
NMR (400 MHz, pyridine-d5) δ 10.11 (s, 1H), 8.52 (s, 1H), 8.04
(s, 1H), 7.40−6.88 (m, 3H), 4.80 (s, 2H), 2.39 (s, 3H), 1.88 (s, 3H). MS
m/z 543 (M + H).
Racemic 2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-N-(3-hy-
droxypiperidin-1-yl)-5-methyl-1H-imidazole-4-carboxamide (13a).
A mixture of racemic 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophen-
yl)-N-(3-hydroxypiperidin-1-yl)-5-methyl-1H-imidazole-4-carboxa-
mide (160mg, 0.29 mmol) and dimethyl sulfide (1.45mmol) in CH2Cl2
under nitrogen atmosphere were treated dropwise with BF3·OEt2
(1.45 mmol). The resulting mixture was stirred for 4 days at ambient
temperature while continuously adding small volumes of CH2Cl2 and
1,4-dioxane. EtOH was added, and the mixture was stirred for 30 min
and then concentrated in vacuo. The residue was dissolved in EtOAc
(50 mL) and washed with water (2 × 20 mL) and brine (20 mL).
Th eorganic layer was dried (Na2SO4), filtered, and concentrated
in vacuo to give the title compound (127 mg, 95%) as a white solid. MS
m/z 461 (M + H).
Racemic 2-(2,4-Dichlorophenyl)-N-(3-hydroxycyclohexyl)-1-(4-
hydroxyphenyl)-5-methyl-1H-imidazole-4-carboxamide (13b). A
suspension of crude 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-
N-(3-hydroxycyclohexyl)-5-methyl-1H-imidazole-4-carboxamide (2.79 g,
5.07mmol) inCH2Cl2 (50mL), and dimethyl sulfide (3.15 g, 50.7mmol)
was treated with boron trifluoride diethyl etherate (5.77 g, 50.7 mmol).
The reaction mixture was stirred at rt for 36 h (dark), adding more
dimethyl sulfide (3.15 g, 50.7 mmol) and boron trifluoride (5.77 g,
50.7 mmol) after 16 h. The solvent was evaporated and the residue
dissolved in EtOAc/water. The phases were separated and the organic
phase dried (MgSO4), filtered, and concentrated in vacuo to yield the
crude title compound (2.54 g). MS m/z 460 (M + H).
Racemic 2-(2,4-Dichlorophenyl)-N-((trans)-2-hydroxycyclohexyl)-
1-(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-carboxamide (13c).
Crude racemic 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-
((trans)-2-hydroxycyclohexyl)-5-methyl-1H-imidazole-4-carboxamide
(2.68 g, 4.87 mmol) was suspended in HBr (33% in AcOH, 60mL). The
mixture was stirred at rt, in the dark, for 1 h 20min. EtOHwas added and
the mixture concentrated in vacuo. The residue was dissolved in MeOH
and neutralized with NaHCO3 (1 M, aq). One spoon of K2CO3 was
added, and the mixture was stirred at rt for 1 h. The solvent was
evaporated, and the resulting mixture extracted with toluene followed by
THF. The combined organic phases were washed with aqueous HCl
(10%) and brine, dried (MgSO4), filtered, and evaporated. The product
was purified by HPLC (30−100% CH3CN in aqueous NH4OAc
(0.1 M) over 40 min) to yield the title compound as a white solid
(829 mg, yield over 2 steps 41%). 1H NMR (400 MHz, CDCl3) δ
7.36−7.18 (m, 4H), 6.86−6.66 (m, 4H), 5.28 (s, 1H), 4.60 (br s, 1H),
3.85−3.74 (m, 1H), 3.52−3.41 (m, 1H), 2.37 (s, 3H), 2.13−1.97 (m,
2H), 1.78−1.67 (m, 2H), 1.44−1.15 (m, 4H). MS m/z 460 (M + H).
Racemic 2-(2,4-Dichlorophenyl)-N-((cis)-2-hydroxycyclohexyl)-1-
(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-carboxamide (13d).
A suspension of racemic 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophen-
yl)-N-((cis)-2-hydroxycyclohexyl)-5-methyl-1H-imidazole-4-carboxa-
mide (2.38 g, 4.33 mmol) in HBr (33% in AcOH, 50 mL). The reac-
tion mixture was stirred at rt, in the dark, for 1 h. EtOH was added and
the solvents were evaporated under reduced pressure. The residue
was dissolved in MeOH and neutralized with aqueous NaHCO3 (1 M).
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The solvent was evaporated and the mixture dissolved in water/CH2Cl2.
The phases were separated, and the organic phase was washed with
brine, dried (MgSO4), filtered, and evaporated. The residue was dis-
solved in MeOH and one spoon of K2CO3 was added, and the resulting
mixture was stirred at rt for 1 h before the solvent was evaporated. The
residue was resuspended in CH2Cl2 and washed with aqueous HCl
(10%), and the solvents were evaporated. The residue was dissolved in
THF, dried (MgSO4), filtered, and evaporated to yield the crude title
compound (2.10 g). 1HNMR (400MHz, THF-d8) δ 8.65 (d, J = 7.3 Hz,
1H), 7.66 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 1.7 Hz, 1H), 7.25 (dd, J = 1.7,
8.3, 1H), 7.18 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 3.99−3.91
(m, 1H), 3.91−3.82 (m, 1H), 3.64−3.55 (m, 1H), 2.47 (s, 3H), 1.86−
1.63 (m, 5H), 1.58−1.44 (m, 1H), 1.38−1.28 (m, 2H). MS m/z 460
(M + H).
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-N-(4-
(trifluoromethoxy)pheny1)-1H-imidazole-4-carboxamide (13e).
Crude 12e (1.35 g, 2.20 mmol) was suspended in HBr (33% in AcOH,
25 mL). The reaction mixture was stirred at rt, in the dark, for 1 h. EtOH
was added, and the solvents were evaporated at reduced pressure. The
residue was dissolved in MeOH and neutralized with aqueous NaHCO3
(1 M). The solvent was evaporated and the mixture dissolved in water/
CH2Cl2. The phases were separated and the organic phase was washed
with brine, dried (MgSO4), filtered, and concentrated in vacuo to yield
the crude title compound (1.10 g). 1H NMR (400 MHz, CDCl3) δ
7.73−7.71 (m, 2H), 7.39−7.16 (m, 5H), 6.94−6.76 (m, 4H), 2.45 (s,
3H). MS m/z 522 (M + H).
2-(2,4-Dichlorophenyl)-N-(6-fluoropyridin-3-yl)-1-(4-hydroxy-
phenyl)-5-methyl-1H-imidazole-4-carboxamide (13f). Compound
12f (1.15 g, 2.10 mmol) was suspended in HBr (33% in AcOH,
25mL). The reactionmixture was stirred at rt, in the dark, for 2 h 30min.
EtOH was added, and the solvents were evaporated under reduced
pressure. The residue was dissolved in MeOH and neutralized with
aqueous NaHCO3 (1 M). The solvent was evaporated and the mixture
dissolved in water/CH2Cl2. The phases were separated, and the organic
phase was washed with brine, dried (MgSO4), filtered, and concentrated
in vacuo to give a residue which was purified by HPLC (30−60%
CH3CN in NH4OAc (0.1 M) over 40 min, then 100% CH3CN) to yield
the title compound as a white solid (519 mg, yield over 2 steps 53%). 1H
NMR (400 MHz, CDCl3) δ 9.14 (s, 1H), 8.37−8.30 (m, 2H), 7.34 (s,
1H), 7.25−7.20 (m, 2H), 6.96−6.90 (m, 3H), 6.79−6.77 (m, 2H), 2.48
(s, 3H). MS m/z 457 (M + H).
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-N-(6-
(trifluoromethyl)pyridin-3-yl)-1H-imidazole-4-carboxamide (13g).
A suspension of crude 12g (1.17 g, 1.96 mmol) in CH2Cl2 (6 mL)
and dimethyl sulfide (1.22 g, 19.6 mmol) was treated with boron
trifluoride (2.78 g, 19.6 mmol). The reaction mixture was stirred at rt for
31 h (dark). Water and CH2Cl2 were added and the phases separated.
The organic phase was washed with water (×4) and concentrated in
vacuo. The residue was dissolved in MeOH and stirred at rt for 20 h
before water was added and theMeOH removed in vacuo. The resulting
mixture was extracted with Et2O (×2), and the combined organic phases
were washed with brine, dried (MgSO4), filtered, and concentrated in
vacuo to yield the crude title compound (776 mg). 1H NMR (400MHz,
CDCl3) δ 9.29 (s, 1H), 8.75 (d, J = 2.1 Hz, 1H), 8.54 (dd, J = 2.1, 8.6 Hz,
1H), 7.64 (d, J = 8.6 Hz, 1H), 7.33 (d, J = 1.7 Hz, 1H), 7.27−7.19 (m,
2H), 6.96 (d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.7 Hz, 1H), 5.51 (br s, 1H),
2.48 (s, 3H). MS m/z 507 (M + H).
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-N-(5-
methylpyridin-2-yl)-1H-imidazole-4-carboxamide (13h). Compound
12h (958 mg, 1.76 mmol) was suspended in HBr (33% in AcOH,
25 mL). The reaction mixture was stirred at rt, in the dark, for 1 h. EtOH
was added, and the solvents were evaporated under reduced pressure.
The residue was dissolved in MeOH and neutralized with aqueous
NaHCO3 (1 M). The solvent was evaporated and the mixture dissolved
in water/CH2Cl2. The phases were separated, and the organic phase was
washed with brine, dried (MgSO4), filtered, and evaporated to yield the
title compound (772 mg, 97%). 1H NMR (400 MHz, pyridine-d5) δ
10.12 (s, 1H), 8.52 (s, 1H), 8.03 (s, 1H), 7.40−6.89 (m, 8H), 2.42 (s,
3H), 1.88 (s, 3H). MS m/z 453 (M + H).
Racemic 4-(2-(2,4-Dichlorophenyl)-4-(3-hydroxypiperidin-1-yl-
carbamoyl)-5-methyl-1H-imidazol-1-yl)phenyl 3,3,3-trifluoropro-
pane-1-sulfonate (14a). A solution of 2-(2,4-dichlorophenyl)-1-(4-
hydroxyphenyl)-N-(3-hydroxypiperidin-1-yl)-5-methyl-1H-imidazole-
4-carboxamide (118 mg, 0.25 mmol) in CH2Cl2 (1 mL), and THF
(1 mL) was treated with Et3N (0.25 mmol) under a nitrogen atmos-
phere. The solution was cooled to −78 °C, and a solution of 3,3,3-
trifluoropropane-1-sulfonyl chloride in CH2Cl2 (1 mL) was added
slowly while monitoring the progress with LC-MS. The reaction mixture
was quenched by addition of EtOH. The reaction mixture was concen-
trated in vacuo, and the residue was purified by reverse phase HPLC
(Kromasil C8, 5−100% CH3CN in aqueous NH4OAc (0.1 M)) and by
flash chromatography (8% EtOH in CH2Cl2). The product was freeze-
dried to give the title compound (40 mg, 25%) as a white powder. 1H
NMR (CD3OD) δ 7.52−7.44 (m, 2H), 7.44−7.34 (m, 5H), 3.91−3.82
(m, 1H), 3.77−3.69 (m, 2H), 3.11 (dd, J = 3.0, 10.1 Hz, 1H), 2.95−2.80
(m, 3H), 2.74−2.58 (m, 2H), 2.46 (s, 3H), 1.95−1.75 (m, 2H),
1.73−1.62 (m, 1H), 1.44−1.31 (m, 1H). MSm/z 621 (M + H). HRMS
Calcd for [C25H25Cl2F3N4O5S + H]: 621.0954. Found: 621.0919.
HPLC: 100%.
Racemic 4-(2-(2,4-Dichlorophenyl)-4-((trans)-3-hydroxycyclohex-
ylcarbamoyl)-5-methyl-1H-imidazol-1-yl)phenyl 3,3,3-trifluoropro-
pane-1-sulfonate (14b). A suspension of crude 2-(2,4-dichlorophen-
yl)-N-(3-hydroxycyclohexyl)-1-(4-hydroxyphenyl)-5-methyl-1H-imi-
dazole-4-carboxamide (2.53 mg, 5.49 mmol) in dry CH2Cl2 (20 mL)
was treated with Et3N (667 mg, 6.59 mmol) at rt. The resulting mixture
was cooled to −78 °C, and 3,3,3-trifluoropropane-1-sulfonyl chloride
(1.30 mg, 6.59 mmol) was added dropwise. After stirring at −78 °C for
2 h 45 min, the reaction mixture was allowed to reach rt, upon which it
was washed with water and evaporated. The stereoisomers were
separated by HPLC (30−100% CH3CN in aqueous NH4OAc (0.1 M))
to yield the trans-hydroxycyclohexyl product (205 mg, 7.5% over
3 steps) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.34−7.23 (m,
5H), 7.20−7.10 (m, 3H), 4.45−4.33 (m, 1H), 4.17−4.10 (m, 1H),
3.55−3.47 (m, 2H), 2.87−2.73 (m, 2H), 2.49 (s, 3H), 2.05−1.51 (m,
8H), 1.48−1.36 (m, 1H). HRMS Calcd for [C26H26Cl2F3N3O5S + H]:
620.1001. Found: 620.1028. HPLC: 100%.
(−) 4-(2-(2,4-Dichlorophenyl)-4-((trans)-2-hydroxycyclohexylcar-
bamoyl)-5-methyl-1H-imidazol-1-yl)phenyl 3,3,3-trifluoropropane-
1-sulfonate (14c). A suspension of racemic 2-(2,4-dichlorophenyl)-N-
((trans)-2-hydroxycyclohexyl)-1-(4-hydroxyphenyl)-5-methyl-1H-imi-
dazole-4-carboxamide (829mg, 1.80 mmol) in dry CH2Cl2 (10mL) was
treated with Et3N (182 mg, 1.80 mmol) at rt. The resulting mixture
was cooled to −78 °C and 3,3,3-trifluoropropane-1-sulfonyl chloride
(354 mg, 1.80 mmol) dry CH2Cl2 (1 mL) was added dropwise. After
stirring at −78 °C for 1 h, the reaction mixture was washed with water
and evaporated. The racemic product was purified by HPLC (30−100%
CH3CN in aqueous NH4OAc (0.1 M) over 40 min) to yield the title
compound as a white solid (710 mg, 64%). 1H NMR (400 MHz,
CDCl3) δ 7.29−7.06 (m, 8H), 3.82−3.62 (m, 2H), 3.50−3.41 (m, 2H),
3.41−3.31 (m, 1H), 2.81−2.65 (m, 2H), 2.43 (s, 3H), 2.09−1.90
(m, 2H), 1.75−1.61 (m, 2H), 1.34−1.12 (m, 4H). HRMS Calcd for
[C26H26Cl2F3N3O5S + H): 620.1001. Found: 620.1011. The (−)-enan-
tiomer was separated from the racemate (535 mg, 0.86 mmol) by chiral
chromatography (Chiralpak AD, heptane:iPrOH 85:15) to afford the
title compound (220 mg) (95.6% ee) as white solid after freeze-drying.
[α]D = −2.9 (c 1.04, CH3CN). 1H NMR (400 MHz, CDCl3) δ 7.29−
7.06 (m, 8H), 3.82−3.62 (m, 2H), 3.50−3.41 (m, 2H), 3.41−3.31 (m,
1H), 2.81−2.65 (m, 2H), 2.43 (s, 3H), 2.09−1.90 (m, 2H), 1.75−1.61
(m, 2H), 1.34−1.12 (m, 4H). HRMS Calcd for [C26H26Cl2F3N3O5S +
H]: 620.1001. Found: 620.0956. HPLC: 100%. Vibrational circular
dichroism experiments were unable to unambiguously assign the
absolute stereochemistry of the (+) and (−) enantiomers.
(+)-4-[2-(2,4-Dichlorophenyl)-4-({[cis-2-hydroxycyclohexyl]-
amino}carbonyl)-5-methyl-1H-imidazol-1-yl]phenyl-3,3,3-trifluoro-
propane-1-sulfonate (14d). A suspension of crude racemic 2-(2,4-
dichlorophenyl)-N-((cis)-2-hydroxycyclohexyl)-1-(4-hydroxyphenyl)-5-
methyl-1H-imidazole-4-carboxamide (2.00 g, 4.34 mmol) in dry CH2Cl2
(30 mL) was treated with Et3N (440 mg, 4.34 mmol) at rt. The resulting
mixture was cooled to −78 °C, and 3,3,3-trifluoropropane-1-sulfonyl
chloride (854 mg, 4.34 mmol) was added dropwise. After stirring at
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−78 °C for 2 h 20 min, more Et3N (2(73 mg, 0.72 mmol)) and 3,3,3-
trifluoropropane-1-sulfonyl chloride (2(110 mg, 0.56 mmol)) were
added (second addition after 1 h). After 2 h, the reaction mixture was
washed with water and evaporated. The racemic product was purified by
HPLC (30−100% CH3CN in aqueous NH4OAc (0.1 M) over 40 min)
to yield the title compounds as a white solid (1.31 g, yield over 2 steps
51%). 1HNMR (400MHz, CDCl3) δ 7.38 (d, J = 7.7 Hz, 1H), 7.28−7.16
(m, 5H), 7.09 (d, J = 8.7 Hz, 2H), 4.13−4.02 (m, 1H), 4.00−3.89 (m,
1H), 3.49−3.38 (m, 2H), 2.80−2.65 (m, 2H), 2.42 (s, 3H), 1.78−1.47
(m, 6H), 1.44−1.28 (m, 2H). HRMS Calcd for [C26H26Cl2F3N3O5S +
H]: 620.1001. Found: 620.1025. The (+)-enantiomer was separated from
the racemate (1.00 g, 1.61 mmol) by chiral chromatography (Chiralpak
AD, heptane/iPrOH 80/20) to yield the title compound (444 mg)
(>99.9% ee) as a white powder after freeze-drying. [α]D = +9.9 (c 1.02,
CH3CN).
1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 7.7 Hz, 1H),
7.28−7.16 (m, 5H), 7.09 (d, J = 8.7 Hz, 2H), 4.13−4.02 (m, 1H), 4.00−
3.89 (m, 1H), 3.49−3.38 (m, 2H), 2.80−2.65 (m, 2H), 2.63−2.53 (m,
1H), 2.42 (s, 3H), 1.78−1.47 (m, 6H), 1.44−1.28 (m, 2H). HRMS
Calcd for [C26H26Cl2F3N3O5S + H] 620.1001. Found: 620.0945.
HPLC: 100%. Vibrational circular dichroism experiments were unable
to unambiguously assign the absolute stereochemistry of the (+) and
(−) enantiomers.
4-(2-(2,4-Dichloropheny1)-5-methy1-4-(4-(trifluoromethoxy)-
phenylcarbamoyl)-1H-imidazol-1-yl)phenyl 3,3, 3-trifluoropropane-
1-sulfonate (14e). A suspension of 13e (150 mg, 0.29 mmol) in dry
CH2Cl2 (2 mL) was treated with Et3N (38 mg, 0.37 mmol) at rt. The
resulting mixture was cooled to −78 °C and 3,3,3-trifluoropropane-1-
sulfonyl chloride (79 mg, 0.40 mmol) in 0.5 mL of dry CH2Cl2 was
added dropwise. After stirring at−78 °C for 70min, the reactionmixture
was washed with water and evaporated. The product was purified by
HPLC (30−100% CH3CN in aqueous NH4OAc (0.1 M) over 35 min)
to yield the title compound as a white solid (84 mg, yield over 3 steps
43%). 1H NMR (400 MHz, CDCl3) δ 9.10 (s, 1H), 7.71 (d, J = 9.0 Hz,
2H), 7.36−7.24 (m, 9H), 7.22−7.15 (m, 4H), 3.54−3.47 (m, 2H),
2.86−2.72 (m, 2H), 2.53 (s, 3H). HRMSCalcd for [C27H19Cl2F6N3O5S
+ H]: 682.0405. Found: 682.0403. HPLC: 100%.
4-(2-(2,4-Dichlorophenyl)-4-(6-fluoropyridin-3-ylcarbamoyl)-5-
methyl-1H-imidazol-1-yl)phenyl 3,3,3-trifluoropropane-1-sulfonate
(14f). A suspension of 2-(2,4-dichlorophenyl)-N-(6-fluoropyridin-3-yl)-
1-(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-carboxamide (150 mg,
0.33 mmol) in dry CH2Cl2 (2 mL) was treated with Et3N (43 mg,
0.43mmol) at rt. The resulting mixture was cooled to−78 °C, and 3,3,3-
trifluoropropane-1-sulfonyl chloride (90 mg, 0.46 mmol) in dry CH2Cl2
(0.5 mL) was added dropwise. After stirring at −78 °C for 2 h 30 min,
more 3,3,3-trifluoropropane-1-sulfonyl chloride (14 mg, 0.07 mmol)
was added and the mixture stirred for another 2 h. The reaction mixture
was washed with water and evaporated. The product was purified by
HPLC (30−100% CH3CN in aqueous NH4OAc (0.1 M) over 35 min)
to yield the title compound as a white solid (133 mg, 66%). 1H NMR
(400 MHz, CDCl3) δ 9.09 (s, 1H), 8.40−8.31 (m, 2H), 7.37−7.24 (m,
5H), 7.19 (d, J = 8.8 Hz, 2H), 6.95−6.88 (m, 1H), 3.55−3−46 (m, 2H),
2.86−2.72 (m, 2H), 2.53 (s, 3H). 13CNMR (126MHz, CDCl3) δ 161.5,
160.7, 158.9, 148.7, 142.6, 138.4 (d, J = 15.1), 137.2, 135.5 (d, J = 38.6),
134.0, 133.3, 133.0 (d, J = 4.5), 132.7 (d, J = 7.5), 130.8, 130.0, 129.4,
127.7, 127.6, 125.1 (q, J = 276.6), 123.2, 109.5 (d, J = 38.8), 44.6 (q, J =
3.3), 29.3 (q, J = 31.9), 11.0. HRMS Calcd for [C25H18Cl2F4N4O4S +
H]: 617.0440. Found: 617.0473. HPLC: 100%.
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(6-(trifluoromethyl)pyridin-
3-ylcarbamoyl)-1H-imidazol-1-yl)phenyl 3,3,3-trifluoropropane-1-
sulfonate (14g). A suspension of crude 13g (150 mg, 0.30 mmol) in
dry CH2Cl2 (2 mL) was treated with Et3N (39mg, 0.38 mmol) at rt then
cooled to−78 °C. To this was added dropwise 3,3,3-trifluoropropane-1-
sulfonyl chloride (91 mg, 0.46 mmol) in dry CH2Cl2 (0.5 mL). After
stirring at −78 °C for 70 min, the mixture was washed with water and
concentrated in vacuo to give a residue which was purified by HPLC
(30−100% CH3CN in aqueous NH4OAc (0.1 M) over 40 min) to yield
the title compound as a white solid (131 mg, yield over 3 steps 52%). 1H
NMR (400 MHz, CDCl3) δ 9.29 (s, 1H), 8.77 (d, J = 2.1 Hz, 1H), 8.56
(dd, J = 2.1, 8.6 Hz, 1H), 7.66 (d, J = 8.6 Hz, 1H), 7.37−7.16 (m, 7H),
3.55−3.46 (m, 2H), 2.86−2.72 (m, 2H), 2.53 (s, 3H). HRMS Calcd for
[C26H18Cl2F6N4O4S + H]: 667.0408. Found: 667.0389. HPLC: 100%.
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(5-methylpyridin-2-ylcar-
bamyl)-1H-imidazol-1-yl)phenyl 3,3,3-trifluoropropane-1-sulfonate
(14h). A suspension of 13h (150 mg, 0.33 mmol) in dry CH2Cl2 (2 mL)
was treated with Et3N (44 mg, 0.43 mmol) at rt. The resulting mixture
was cooled to −78 °C, and 3,3,3-trifluoropropane-1-sulfonyl chloride
(94 mg, 0.48 mmol) in dry CH2Cl2 (0.5 mL) was added dropwise. After
stirring at −78 °C for 80 min, the reaction mixture was washed with
water and evaporated. The product was purified by HPLC (30−100%
CH3CN in aqueous NH4OAc (0.1 M) over 40 min) to yield the title
compound as a white solid (132 mg, 65%). 1H NMR (400 MHz,
CDCl3) δ 9.63 (s, 1H), 8.23 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 1.4 Hz, 1H),
7.51 (dd, J = 2.1, 8.4 Hz, 1H), 7.34−7.24 (m, 5H), 7.18 (d, J = 8.9 Hz,
2H), 3.55−3.44 (m, 2H), 2.86−2.71 (m, 2H), 2.53 (s, 3H), 2.28 (s, 3H).
HRMS Calcd for [C26H21Cl2F3N4O4S + H]: 613.0691. Found:
613.0702. HPLC: 100%.
2,2,2-Trichloroethyl-1-(4-(benzyloxy)phenyl)-2-(2,4-dichloro-
phenyl)-5-methyl-1H-imidazole-4-carboxylate (15). A solution of
compound 4 (10.0 g, 22.1 mmol) in CH2Cl2 (210 mL) was treated with
oxalyl chloride (18.5 g, 145 mmol), followed by a few drops of DMF.
The mixture was stirred at rt for 2 h, after which the solvents were
evaporated. The residue was dissolved in CH2Cl2 (80 mL) and the
mixture was cooled to 0 °C, upon which 2,2,2-trichloroethanol (3.63 g,
24.3 mmol) was added followed by DIPEA (3.42 g, 26.5 mmol). The ice
bath was then removed, and the reaction mixture was stirred at rt for 3 h,
adding DMAP (279 mg, 2.28 mmol) after 1 h 40 min. The reaction
mixture was diluted with CH2Cl2, washed with water, dried (MgSO4),
filtered, and concentrated in vacuo to yield the crude title compound
(14.9 g). 1H NMR (400MHz, CDCl3) δ 7.40−7.14 (m, 8H), 7.04−6.98
(m, 2H), 6.94−6.88 (m, 2H), 5.01 (4H, s), 2.45 (s, 3H). MS m/z 583
(M + H).
2,2,2-Trichloroethyl-2-(2,4-dichlorophenyl)-1-(4-hydroxyphenyl)-
5-methyl-1H-imidazole-4-carboxylate (16). Crude 15 (14.77 g) was
dissolved in HBr (33% in AcOH, 200 mL). After having stirred at rt for
an additional hour, the reaction mixture was cooled to 0 °C and EtOH
was added. The mixture was stirred for 10 min before the solvents were
evaporated. The residue was dissolved in MeOH and neutralized with
aqueous NaHCO3 (1 M). The solvent was evaporated and the mixture
dissolved in CH2Cl2. The organic phase was washed with brine and
water, dried (MgSO4), filtered, and concentrated in vacuo to yield the
title compound (10.4 g, 95% over 2 steps). 1HNMR (400MHz, CDCl3)
δ 8.63 (br s, 1H), 7.25−7.08 (m, 3H), 6.86−6.68 (m, 4H), 4.95 (s, 2H),
2.43 (s, 3H). MS m/z 493 (M + H).
2,2,2-Trichloroethyl-2-(2,4-dichlorophenyl)-5-methyl-1-(4-(3,3,3-
trifluoropropylsulfonyloxy)phenyl)-1H-imidazole-4-carboxylate
(17). A suspension of 16 (5.01 g, 10.13 mmol) in dry CH2Cl2 (100 mL)
under nitrogen was treated with Et3N (1.23 g, 12.2 mmol) at rt. The
resulting mixture was cooled to −78 °C, and 3,3,3-trifluoropropane-1-
sulfonyl chloride (2.19 g, 11.1 mmol) was added dropwise. The reaction
mixture was stirred at −78 °C for 3 h, adding more 3,3,3-trifluoro-
propane-1-sulfonyl chloride (0.28 g 1.43 mmol) after 2 h. Water was
added and the phases were separated on a phase separator. The organic
phase was concentrated in vacuo to yield the title compound (6.43 g,
97%). 1H NMR (400 MHz, CDCl3) δ 7.37−7.15 (m, 7H), 5.01
(s, 2H), 3.53−3.45 (m, 2H), 2.84−2.70 (m, 2H), 2.48 (s, 3H). MS m/z
653 (M + H).
2-(2,4-Dichlorophenyl)-5-methyl-1-(4-(3,3,3-trifluoropropylsulfo-
nyloxy)phenyl)-1H-imidazole-4-carboxylic Acid (18). A solution of 17
(6.43 g, 9.82 mmol) in AcOH (100 mL) was treated with zinc dust
(9.74 g, 148.91 mmol). The reaction mixture was stirred at rt for 3 h,
after which it was filtered through Celite and evaporated. The residue
was dissolved in CH2Cl2 and washed with aqueous HCl (0.1 M), dried,
filtered, and concentrated in vacuo to yield the crude title compound
(5.28 g). MS m/z 523 (M + H).
4-(2-(2,4-Dichlorophenyl)-4-(4-hydroxycyclohexylcarbamoyl)-5-
methyl-1H-imidazol-1-yl)phenyl 3,3,3-trifluoropropane-1-sulfonate
(19). A solution of 18 (crude 528 mg) in CH2Cl2 (25 mL) was treated
with oxalyl chloride (641 mg, 5.00 mmol). A precipitate formed imme-
diately after the addition so more CH2Cl2 (15 mL) was added, followed
by a few drops of DMF. The reaction mixture was stirred at rt for 2 h,
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after which more oxalyl chloride (641 mg, 5.00 mmol) was added. After
another 10 min the solvents were evaporated. Half of the crude material
was suspended in CH2Cl2 (5 mL) and added dropwise to a mixture of
4-aminocyclohexanol (74 mg, 0.64 mmol), NaOH (1 M, 10 mL), and
CH2Cl2 (5 mL). The reaction mixture was stirred at rt for 2 h, after
which water/CH2Cl2 were added and the phases separated. The organic
phase was washed with aqueousHCl (0.1M) and concentrated in vacuo.
The product was purified by HPLC to yield the title compound as a
white solid after freeze-drying (164 mg, 54% over 2 steps). Note that the
title compound is a mixture of cis- and trans- isomers in a ratio of 0.3:1.
1HNMR (400MHz, CDCl3) δ 7.33−7.19 (m, 6H), 7.17−7.11 (m, 2H),
7.02 (d, J = 8.4 Hz, 0.6H), 4.07−3.99 (m, 0.3H), 3.99−3.86 (1H, m),
3.66−3.56 (m, 0.6H), 3.52−3.45 (m, 2H), 2.85−2.71 (m, 2H), 2.48 and
2.47 (2s, 3H), 2.12−1.95 (m, 2.6H), 1.81−1.65 (m, 3.8H), 1.49−1.26
(m, 2.7H). HRMS Calcd for [C26H26Cl2F3N3O5S + H]: 620.1001.
Found: 620.1002. HPLC: 100%.
Racemic N-((cis)-2-Aminocyclohexyl)-1-[4-(benzyloxy)phenyl)-2-
(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxamide (20).
A suspension of compound 4 (2.00 g, 4.41 mmol) in CH2Cl2 (50 mL)
was treated with oxalyl chloride (2.80 mg, 22.1 mmol) at rt, followed by
one drop of DMF. The mixture was stirred at rt for 30 min, after which
the solvents were evaporated under reduced pressure. Half of the
amount of the acid chloride (1.04 mg, 2.20 mmol) suspended in CH2Cl2
(250 mL) was added dropwise during 31 h to a mixture of (cis)-
cyclohexane-1,2-diamine (5.00 mg, 43.79 mmol), aqueous NaOH (1M,
50 mL), and CH2Cl2 (50 mL). After the addition was complete, water
was added and the phases were separated. The organic phase was
washed with aqueous HCl (10%) and brine, dried (MgSO4), filtered,
and evaporated to yield the crude title compound (1.31 mg). 1H NMR
(400 MHz, CDCl3) δ 8.57 (br s, 2H), 7.69 (br s, 1H), 7.37−6.90 (m,
2H), 5.00 (s, 2H), 4.41 (br s, 1H), 3.72 (br s, 1H), 2.42 (s, 3H), 2.18−
1.40 (m, 8H). MS m/z 549 (M + H).
Racemic N-((cis)-2-Aminocyclohexyl)-2-(2,4-dichlorophenyl)-1-(4-
hydroxyphenyl)-5-methyl-1H-imidazole-4-carboxamide (21). A sus-
pension of crude racemic 20 (791 mg, 1.44 mmol) in CH2Cl2 (5 mL)
and dimethyl sulfide (894 mg, 14.39 mmol) was treated with boron
trifluoride (2.04 g, 14.4 mmol). The reaction mixture was stirred at rt for
2.5 days (dark). Water and EtOAc were added and the phases separated.
The organic phase was dried (MgSO4), filtered, and evaporated to yield
the crude title compound (715 mg). MS m/z 459 (M + H).
Racemic 4-(4-((cis)-2-Aminocyclohexylcarbamoyl-2-(2,4-dichlor-
ophenyl)-5-methyl-1H-imidazol-1-yl)phenyl 3,3,3-trifluoropropane-
1-sulfonate (22).A suspension of crude racemic 21 (715mg, 1.56mmol)
in CH2Cl2 (15 mL) and Et3N (0.987 g, 9.76 mmol) was treated with
TBDMSCl (0.985 g, 6.53 mmol). The reaction mixture was stirred at rt
for 22 h. CH2Cl2 and water were added and the phases separated. The
organic phase was dried (MgSO4), filtered, and evaporated to yield the
crude silylated intermediate an oil (1.14 g, 1.99 mmol). MS m/z 573
(M + H). A solution of the crude intermediate (1.14 g, 1.99 mmol) in
THF (10 mL) was treated with (Boc)2O (444 mg, 2.03 mmol). The
reaction mixture was stirred at rt for 4 h, after which the solvent was
evaporated at reduced pressure and the residue dissolved in CH2Cl2.
The organic phase was washed with water, dried (MgSO4), filtered, and
concentrated in vacuo. The residue was purified by flash chromatog-
raphy (10−100% EtOAc in heptane) to yield the Boc-protected
intermediate (620 mg, yield over 4 steps 70%). 1H NMR (400 MHz,
CDCl3) δ 7.37 (d, J = 8.2 Hz, 1H), 7.24−7.08 (m, 3H), 6.85 (d, J = 8.7
Hz, 2H), 6.70 (d, J = 8.7 Hz, 2H), 5.12 (d, J = 4.5 Hz, 1H), 4.32−4.19
(m, 1H), 3.83−3.74 (m, 1H), 2.38 (s, 3H), 1.79−1.39 (m, 8H), 1.33
(s, 9H), 0.87 (s, 9H), 0.11 (s, 6H). MSm/z 673 (M + H). A suspension
of the fully protected intermediate (610 mg, 0.91 mmol) in dry THF
(3 mL) was treated with TBAF (1.0 M THF, 237 mg, 0.91 mmol). The
reaction mixture was stirred at rt for 1 h 45 min. The solvent was
evaporated and the residue dissolved in CH2Cl2, washed with water,
dried (MgSO4), filtered, and evaporated. The residue was dissolved in
EtOAc, and some silica gel was added. The suspension was filtered
through a plug of silica gel and eluted with EtOAc. The solvent
was evaporated to yield the crude desilylated intermediate (529 mg).
1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.1 Hz, 1H), 7.21 (d, J =
1.6 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 7.09 (dd, J = 1.6, 8.3 Hz, 1H), 6.80
(d, J = 8.6 Hz, 2H), 6.68 (d, J = 8.6 Hz, 2H), 5.07 (d, J = 6.6 Hz, 1H),
4.28−4.16 (m, 1H), 3.84−3.72 (m, 1H), 2.32 (s, 3H), 1.55−1.37 (m,
8H), 1.31 (9H, s). MS m/z 559 (M + H). A suspension of the crude
intermediate (506 mg, 0.91 mmol) in dry CH2Cl2 (6 mL) was treated
with Et3N (110 mg, 1.09 mmol) at rt. The resulting mixture was cooled
to −78 °C, and 3,3,3-trifluoropropane-1-sulfonyl chloride (181 mg,
0.92 mmol) in dry CH2Cl2 (0.2 mL) was added dropwise. After stirring
at−78 °C for 3 h (including extra additions of 3,3,3-trifluoro-propane-1-
sulfonyl chloride (2 × 43 mg, 0.22 mmol) after 1.5 and 2.5 h), the
reaction mixture was washed with water and evaporated to yield the
crude intermediate (655 mg). MS m/z 719 (M + H). To a suspension
of the Boc-protected intermediate (655 mg, 0.91 mmol) in MeOH
(10 mL) at 0 °C was added dropwise, a solution of thionyl chloride
in MeOH (prepared by dropwise addition of thionyl chloride (5.41 g,
45.5 mmol) to MeOH (10 mL) at −40 °C). After the addition, the ice
bath was removed. The reaction mixture was stirred at rt for 1 h, after
which the solvents were evaporated. The product was purified by HPLC
(30−100% CH3CN (with 0.1% formic acid) in 0.1% formic acid (aq)
during 40 min). The CH3CN was evaporated and the resulting mixture
extracted with CH2Cl2. The organic phase was washed with aqueous
NaHCO3 (1 M), dried (MgSO4), filtered, and concentrated in vacuo to
yield the title compound as a slightly yellow solid (315 mg yield over 3
steps 56%). 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.7 Hz, 1H),
7.32−7.20 (m, 5H), 7.14 (d, J = 8.8 Hz, 2H), 4.20−4.09 (m, 1H), 3.52−
3.44 (m, 2H), 3.15−3.06 (m, 1H), 2.84−2.71 (m, 2H), 2.47 (s, 3H),
1.70−1.39 (m, 10H). HRMS Calcd for [C26H27Cl2F3N4O4S + H]:
619.1160. Found: 619.1216. HPLC: 95.4%.
Racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-((cis)-
2-(dimethylamino)cyclohexyl)-5-methyl-1H-imidazole-4-carboxa-
mide (23). To a suspension of racemic 20 (493 mg, 0.90 mmol) in
CH3CN (10 mL) was added formaldehyde, 36% (135 mg, 4.49 mmol),
and sodium borohydride (75 mg, 1.97 mmol) in portions. The sus-
pension was stirred at rt for 2 days, adding 2.5 h afterward sodium
borohydride (77 mg, 2.04 mmol), 3.5 h afterward formaldehyde (36% in
H2O, 67 mg, 2.24 mmol), 18.5 h afterward formaldehyde (36% in H2O,
67 mg, 2.24 mmol), and sodium borohydride (77 mg, 2.04 mmo1) (the
temperature was increased to 40 °C for 4.5 h), 23 h afterward AcOH
(1.85 mL) at rt, and 28 h afterward formaldehyde (36% in H2O, 135 mg,
4.49mmol), followed by sodium cyanoborohydride (112mg, 1.78mmol)
and 42 h later, formaldehyde (36% in H2O, (135 mg, 4.49 mmol),
followed by sodium cyano borohydride (126 mg, 2.01 mmol). The
reaction mixture was diluted with CH2Cl2, washed with NaOH (1 M)
and brine, dried (MgSO4), filtered, and evaporated. The residue was
purified by HPLC (30−100% CH3CN in aqueous NH4OAc (0.1 M)
over 30 min). The CH3CN was evaporated and the resulting mixture
extracted with CH2Cl2, dried (MgSO4), filtered, and evaporated to yield
the title compound (163 mg, 32%). MS m/z 577 (M + H).
Racemic 2-(2,4-Dichlorophenyl)-N-((cis)-2-(dimethylamino)-
cyclohexyl)-1-(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-carbox-
amide (24). A suspension of racemic 23 (163 mg, 0.28 mmol) in
CH2Cl2 (2 mL) and dimethyl sulfide (351 mg, 5.64 mmol) was treated
with boron trifluoride (801 mg, 5.64 mmol). The reaction mixture was
stirred at rt for 2 days (dark), adding more of dimethyl sulfide (176 mg,
2.82mmol) and boron trifluoride (401mg, 2.82mmol) after 17 h.Water
and CH2Cl2 were added and the phases separated. The organic phase
was washed with water, dried (MgSO4), filtered, and concentrated in
vacuo to yield the crude title compound (104mg). MSm/z 487 (M+H).
Racemic 4-(2-(2,4-Dichlorophenyl)-4-((cis)-2-(dimethylamino)-
cyclohexylcarbamoyl)-5-methyl-1H-imidazol-1-yl]phenyl 3,3,3-tri-
fluoropropane-1-sulfonate (25). A suspension of racemic 24 (104 mg,
0.21 mmol) in dry CH2Cl2 (1.5 mL) was treated with Et3N (26 mg,
0.26 mmol) at rt. The resulting mixture was cooled to−78 °C, and 3,3,3-
trifluoropropane-1-sulfonyl chloride (50 mg, 0.26 mmol) in dry CH2Cl2
(0.5 mL) was added dropwise. After stirring at −78 °C for 6.5 h (and
adding more 3,3,3-trifluoropropane-1-sulfonyl chloride (2 × 50 mg,
0.26 mmol) after 2 and 4 h, and Et3N (26 mg, 0.26 mmol) after 4 h), the
reaction mixture was washed with water and evaporated. The residue
was purified by HPLC (30−100% CH3CN (with 0.1% formic acid) in
0.1% formic acid over 40 min) and freeze-dried. The product was
dissolved in CH2Cl2 and washed with NaHCO3 (1 M) and water, dried
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(MgSO4), filtered, and concentrated in vacuo to yield the title com-
pound as a slightly yellow oil (37 mg yield over 2 steps 20%). 1H NMR
(400 MHz, CDCl3) δ 7.54 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H),
7.31 (d, J = 2.0 Hz, 1H), 7.29 (d, J = 8.9 Hz, 1H), 7.26 (dd, J = 2.0,
8.3 Hz, 1H), 7.17 (d, J = 8.9Hz, 1H), 4.59−4.51 (m, 1H), 3.56−3.48 (m,
2H), 2.86−2.76 (m, 2H), 2.51 (s, 3H), 2.31 (s, 6H), 2.26−2.19 (m, 1H),
2.07 (dt, J = 3.8, 11.8 Hz, 1H), 2.04−1.96 (m, 2H), 1.85−1.77 (m, 1H),
1.54−1.25 (m, 5H). HRMS Calcd for [C28H31Cl2F3N4O4S + H]:
647.1473. Found: 647.1472. HPLC: 100%.
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(5-
(trifluoromethyl)pyridin-2-yl)-1H-imidazole-4-carboxamide (26). A
solution of 2-amino-5-(trifluoromethyl)pyridine (404 mg, 2.49 mmol)
in CH2Cl2 (2.5 mL) under argon was carefully treated with trimeth-
ylaluminum (2.0 M in toluene, 1.25 mL, 2.5 mmol) over 5 min. The
solution was stirred at rt for 1.5 h to give a 0.66 M solution of the
amidation reagent. A portion of this solution (3.75 mL, 2.5 mmol) was
added to compound 3 (400 mg, 0.83 mmol). After stirring at 45 °C
overnight, the mixture was cooled to 0 °C and quenched with HCl (aq,
2 M, 7.5 mL). The mixture was diluted with dichloromethane and neu-
tralized by addition of KOH (aq, 2M). The organic phase was separated,
and the aqueous phase was extracted further with dichloromethane. The
collected organic phases were washed with H2O, dried (Na2SO4),
filtered, and concentrated in vacuo to give a residue which was purified
by preparative HPLC to give the title compound (319 mg, 64%) as a
solid. 1H NMR (400 MHz, CDCl3) δ 9.91 (s, 1H), 8.57 (s, 1H), 8.52
(d, J = 8.8 Hz, 1H), 7.92 (dd, J = 2.1, 8.8 Hz, 1H), 7.44−7.32 (m, 6H),
7.30−7.21 (m, 2H), 7.04 (d, J = 8.9 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H),
5.05 (s, 2H), 2.52 (s, 3H). MS m/z 597 (M + H).
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-N-(5-
(trifluoromethyl)pyridin-2-yl)-1H-imidazole-4-carboxamide (27).
Compound 26 (319 mg, 0.53 mmol) was dissolved in HBr (4.1 M in
acetic acid, 7.5 mL, 30.8 mmol) and the mixture stirred at rt for 4 h. The
acetic acid was co-evaporated with EtOH and the residue neutralized
with ammonia and dissolved in methanol. Purification by flash chroma-
tography gave the title compound (266 mg, 98%). 1H NMR (400 MHz,
DMF-d7) δ 10.36 (s, 1H), 10.09 (s, 1H), 8.89 (d, J = 1.0 Hz, 1H), 8.69
(d, J = 8.9 Hz, 1H), 8.45 (dd, J = 1.0, 8.9 Hz, 1H), 7.85 (d, J = 8.3 Hz,
1H), 7.80 (s, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 8.4 Hz, 2H), 7.06
(d, J = 8.4 Hz, 2H), 2.65 (s, 3H). MS m/z 507 (M + H).
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(5-(trifluoromethyl)pyridin-
2-ylcarbamoyl)-1H-imidazol-1-yl)phenyl 3,3,3-trifluoropropane-1-
sulfonate (28). A mixture of 27 (136 mg, 0.27 mmol) and Et3N (40 μL,
0.32 mmol) in CH2Cl2 (4.0 mL) was cooled to −78 °C then carefully
treated with 3,3,3-trifluoropropane-1-sulfonyl chloride (63 mg,
0.32 mmol). The resulting mixture was stirred at −78 °C for 1 h, then
allowed to reach room temperature. Water was added to the reaction,
and the phases were separated. The organic phase was washed with
NaHCO3 and brine, then dried (Na2SO4), filtered, and concentrated in
vacuo to give a residue which was purified by preparative HPLC to give
the title compound (88 mg, 49%) as a solid. 1H NMR (400 MHz,
CDCl3) δ 9.87 (s, 1H), 8.55 (s, 1H), 8.49 (d, J = 8.8 Hz, 1H), 7.91 (dd,
J = 2.1, 8.8 Hz, 1H), 7.36−7.21 (m, 5H), 7.19 (d, J = 8.8 Hz, 2H), 3.55−
3.46 (m, 2H), 2.87−2.71 (m, 2H), 2.54 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ 162.0, 154.3, 148.6, 145.6 (q, J = 4.1), 142.7, 137.0, 136.2,
135.6 (q, J = 3.2), 135.2, 134.1, 133.4, 131.0, 130.0, 129.3, 127.9, 127.5,
125.1 (q, J = 277.1), 123.8 (q, J = 271.3), 123.2, 122.1 (q, J = 32.7),
113.1, 44.5 (q, J = 3.3), 29.3 (q, J = 31.5), 11.1. HRMS Calcd for
[C26H18Cl2F6N4O4S + H]: 667.0408. Found: 667.0540. HPLC: 100%.
Biology. Chemicals and Reagents. [3H]CP55940 (specific activity
141.2 Ci/mmol) was purchased from PerkinElmer (Waltham, MA).
Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained
from Pierce Chemical Company (Rochford, IL). Rimonabant was from
Cayman Chemical Company (Ann Arbor, MI). CHOK1hCB1_bgal cells
(catalogue number 93-0959C2) were obtained from DiscoveRx
(Fremont, CA). Themembranes (catalogue number RBHCB1M400UA)
used for [35S]GTPyS antagonism experiment were purchased from
PerkinElmer (Waltham, MA). All other chemicals were of analytical
grade and obtained from standard commercial sources.
Cell Culture and Membrane Preparation. CHOK1hCB1_bgal cells
were cultured in Ham’s F12 Nutrient Mixture supplemented with 10%
fetal calf serum, 1 mM glutamine, 50 μg/mL penicillin, 50 μg/mL
streptomycin, 300 mg/mL hygromycin, and 800 μg/mL Geneticin in a
humidified atmosphere at 37 °C and 5% CO2. Cells were subcultured
twice a week at a ratio of 1:10 on 10 cm diameter plates by trypsinization.
For membrane preparation, the cells were subcultured 1:10 and trans-
ferred to large 15 cm diameter plates. Membrane fractions were
prepared exactly as described before.50
Equilibrium Radioligand Displacement Assays. [3H]CP55940
displacement assays on 96-well plate were used for the determination
of affinity (IC50 and Ki) values of antagonists for the cannabinoid CB1
receptors. The displacement experiments were performed using six
concentrations of competing antagonists in 25 μL of assay buffer
(50 mM Tris-HCl, 5 mMMgCl2, 0.1% BSA, pH 7.4) in the presence of
another 25 μL of assay buffer with a final concentration of 3.5 nM
[3H]CP55940. At this concentration, total radioligand binding did not
exceed 10% of that added to prevent ligand depletion. Membrane
aliquots containing 5 μg of CHOK1hCB1_bgal membrane in 100 μL of
assay buffer were incubated at 30 °C for 60 min. Nonspecific binding
(NSB) was determined in the presence of 10 μM rimonabant. Incuba-
tion was terminated by rapid filtration performed on 96-well GF/C filter
plates (PerkinElmer, Groningen, The Netherlands), presoaked for
30 min with 0.25% PEI (Polyethyleneimine), using a PerkinElmer
Filtermate harvester (PerkinElmer, Groningen, The Netherlands). After
30 min of dehydration of the filter plate at 50 °C, the filter-bound
radioactivity was determined by scintillation spectrometry using the
2450 MicroBeta2 plate counter. The binding values were recorded in
both counts per minute (CPM) and disintegrations per minute (DPM).
Each antagonist was measured in duplicate, and at least three individual
experiments were performed.
Classic Radioligand Kinetic Assays. Association experiments were
performed by incubating membrane aliquots containing 5 μg of
CHOK1hCB1_bgal membrane in a total volume of 100 μL of assay
buffer at 30 °C with 3.5 nM [3H]CP55940. The amount of radioligand
bound to the receptor was measured at different time intervals during a
total incubation of 120 min. Dissociation experiments were performed
by preincubatingmembrane aliquots containing 5 μg of protein in a total
volume of 100 μL of assay buffer for 60 min. After the preincubation,
radioligand dissociation was initiated by the addition of 10 μMunlabeled
rimonabant. The amount of radioligand still bound to the receptor was
measured at various time intervals for a total of 240 min to ensure that
full dissociation from cannabinoid CB1 receptor was reached. Incubation
was terminated by rapid filtration performed on GF/C filters (Whatman
International, Maidstone, UK), presoaked for 30 min with 0.25% PEI,
using a Brandel harvester (Brandel, Gaithersburg, MD). Filter-bound
radioactivity was determined by scintillation spectrometry using a Tri-
Carb 2900 TR liquid scintillation counter (PerkinElmer, Boston, MA).
Competition Association Assays.Kinetic rate index (KRI) values are
an average of at least two independent experiments, each consisting of
two replicates. Kinetic rate constant values are an average of at least three
independent experiments, each consisting of two replicates. The binding
kinetics of unlabeled ligands was quantified using the competi-
tion association assay based on the theoretical framework by Motulsky
and Mahan.36 A concentration of 1−3-fold of the IC50 value was used to
determine the binding kinetics of unlabeled CB1 receptor antagonists.
The competition association assay was initiated by adding mem-
brane aliquots (5 μg/well) at different time points for a total of 240 min
to a total volume of 100 μL of assay buffer at 30 °C with 3.5 nM
[3H]CP55940 in the absence or presence of competing CB1 receptor
antagonists (1 to 3-fold IC50). Incubations were terminated, and samples
were obtained as described under Equilibrium Radioligand Displace-
ment Assay. The “dual-point” competition association assays32 were run
similarly, with only two time points, at 30 and 240 min, respectively.
[35S]GTPγS Binding Assays. Antagonism assay: The antagonism of all
tested compounds was evaluated at 30 °C in a [35S]GTPγS binding assay
as reported earlier.51 Insurmountability assay: Membrane homogenates
containing the CB1 receptor (5 μg) were equilibrated in the assay buffer
(50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 100 mM NaCl, 0.05%
BSA, pH7.4) supplemented with 1 μM GDP, 1 mM DTT, and 5 μg of
saponin. Membrane preparations were preincubated with or without
antagonists (10-fold Ki values on the CB1 receptor) for 1 h prior to the
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challenge of a CB1 receptor agonist, CP55940 at 25 °C with concentra-
tions ranging from 1 μM to 0.1 nM. Subsequently, [35S]GTPγS (final
concentration 0.3 nM) was added and incubation continued for another
30min at 25 °C. Incubations were terminated, and samples were obtained
as described under Equilibrium Radioligand Displacement Assays.
Data Analysis. All experimental data were analyzed using the non-
linear regression curve fitting program GraphPad Prism 6.0 (GraphPad
Software, Inc., San Diego, CA). From displacement assays, IC50 values
were obtained by nonlinear regression analysis of the displacement
curves. The obtained IC50 values were converted into Ki values using the
Cheng−Prusoff equation to determine the affinity of the ligands.52 The
kon and koff values for radiolabeled and unlabeled ligands were fitted and
calculated, and the kon and koff values were used to calculate residence
times (in min) and kinetic dissociation binding constants (kinetic KD).
Association and dissociation rates for unlabeled compounds were
calculated by fitting the data into the competition association model
using “kinetics of competitive binding”:36
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where k1 is the kon of the radioligand (M
−1 s−1), k2 is the koff of the
radioligand (s−1), L is the radioligand concentration (nM), I is the
concentration of the unlabeled competitor (nM), and X is the time
(min) and Y is the specific binding of the radioligand (DPM). During a
competition association, these parameters are set, obtaining k1 from the
control curve without competitor and k2 from previously performed
dissociation assays described under Traditional Radioligand Kinetic
Assays. With that, the k3, k4 and Bmax can be calculated, where k3 repre-
sents the kon (M
−1 s−1) of the unlabeled ligand, k4 stands for the koff (s
−1)
of the unlabeled ligand, and Bmax equals the total binding (DPM). All
competition association data were globally fitted. Residence times (RT,
expressed in min) were calculated as RT = 1/(60 × koff).
Computational Studies. All computational studies were per-
formed in the Schrödinger suite53 and based on the crystal structure of
the CB1 receptor co-crystallized with 29 (PDB 5TGZ).
33 The crystal
structure was prepared with the Protein Preparation Wizard.53 Ligands
were docked using induced fit docking,54 with core constraints on the
2,4-dichlorophenyl ring of 29 (all ligands share this moiety). To study
whether the difference in RTs among 11d, 14f, and 28 could be
explained by unfavorable hydration, we generated a WaterMap around
14f.47,48 Figures were rendered using PyMol.55
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